var title_f10_55_11120="Apposition of the skin edges following fasciotomy";
var content_f10_55_11120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apposition of the skin edges following fasciotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 632px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silastic bands or nylon sutures may be used in a \"Roman-sandle\" configuration to progressively reapproximate the skin edges after fasciotomy. Multiple skin staples are placed along the entire length of the incision on both sides of the wound. Through these staples, silastic bands or heavy gauge nylon sutures are placed in a shoelace or \"Roman-sandle\" configuration. By gently pulling the ends of the silastic bands (or sutures), the skin edges are pulled together. This procedure may be repeated multiple times over several days to reapproximate the skin edges and narrow or close the wound entirely. Although the skin is reapproximated, the fascia is not closed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11120=[""].join("\n");
var outline_f10_55_11120=null;
var title_f10_55_11121="Ulcerative sarcoidosis";
var content_f10_55_11121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerative sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerative sarcoidosis. Atrophic, hyperpigmented plaques are present; the inferior lesion is ulcerated. These ulcerations are often misdiagnosed as venous ulcers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11121=[""].join("\n");
var outline_f10_55_11121=null;
var title_f10_55_11122="Attapulgite: Pediatric drug information";
var content_f10_55_11122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Attapulgite: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34082?source=see_link\">",
"    see \"Attapulgite: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kaopectate&reg; Children&rsquo;s [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34082?source=see_link\">",
"      see \"Attapulgite: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate controlled clinical studies documenting the efficacy of attapulgite are lacking; its usage and dosage has been primarily empiric; the following are manufacturer's recommended dosages",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Oral: Give after each bowel movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-6 years: 300-750 mg/dose; maximum dose: 7 doses/day or 2250 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 600-1500 mg/dose; maximum dose: 7 doses/day or 4500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 1200-3000 mg/dose; maximum dose: 8 doses/day or 9000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; shake liquid preparation well before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of uncomplicated diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kaopectate&reg; may be confused with Kayexalate&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <b>",
"        Note:",
"       </b>",
"       Attapulgite preparations have been discontinued in the U.S.; refer to Bismuth monograph for newly-reformulated Kaopectate&reg; products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to attapulgite or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not to be used for self-medication for diarrhea &gt;48 hours or in the presence of high fever in infants and children &lt;3 years of age; do not use for diarrhea associated with pseudomembranous enterocolitis or in diarrhea caused by toxigenic bacteria",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls diarrhea because of its absorbent action",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed maximum number of doses per day; drink plenty of fluids; contact your physician if diarrhea persists more than 48 hours or if fever develops in children &lt;3 years of age",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kaopectate&reg;, Kaopectate&reg; Advanced Formula, Children's Kaopectate&reg;, and Kaopectate&reg; Maximum Strength have been reformulated. Previously, Kaopectate&reg; contained attapulgite. The new formulation contains only bismuth subsalicylate. Bismuth salicylate has significant contraindications, particularly in children with influenza and chickenpox. Please refer to bismuth monograph for product information. During the transition period, the older formulation may still be available, read product label closely.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12891 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11122=[""].join("\n");
var outline_f10_55_11122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138012\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056682\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056677\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217267\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056685\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056684\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138027\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056676\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056675\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056681\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056688\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34082?source=related_link\">",
"      Attapulgite: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11123="Substernal goiter PA";
var content_f10_55_11123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Chest x-ray showing tracheal deviation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray showing a substernal goiter appearing as a paratracheal mass deviating the trachea to the right (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11123=[""].join("\n");
var outline_f10_55_11123=null;
var title_f10_55_11124="Clinical pathological cases in gastroenterology: Esophagus";
var content_f10_55_11124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical pathological cases in gastroenterology: Esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11124/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11124/contributors\">",
"     Andres Gelrud, MD, MMSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11124/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11124/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/55/11124/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following cases are meant to illustrate clinical, pathological, and endoscopic findings in patients with a variety of esophageal conditions. Detailed discussions on the specific disorders are presented on corresponding topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PILL ESOPHAGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 62 year old woman awakened with severe odynophagia and dysphagia. Her only medical problem is osteoporosis treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (Fosamax&reg;) over the past eight months. Her weight has been stable and she denies having fevers, nausea, vomiting, or abdominal pain. She denies a prior history of dysphagia. An upper endoscopy was performed (",
"    <a class=\"graphic graphic_picture graphicRef76438 graphicRef55447 \" href=\"UTD.htm?34/42/35489\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLYCOGEN ACANTHOSIS AND BARRETT'S ESOPHAGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 36 year old obese male underwent an upper endoscopy with biopsies for the evaluation of worsening heartburn over the past nine months. He has no other medical problems and denies any nausea, vomiting, abdominal pain, odynophagia, dysphagia, or weight loss. Endoscopy revealed multiple elevated gray-white nodules in the upper and middle third of the esophagus (",
"    <a class=\"graphic graphic_picture graphicRef56274 \" href=\"UTD.htm?33/57/34718\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67987 \" href=\"UTD.htm?15/40/16001\">",
"     picture 3",
"    </a>",
"    ) A long segment of salmon colored mucosa was seen in the distal esophagus (",
"    <a class=\"graphic graphic_picture graphicRef79495 \" href=\"UTD.htm?1/58/1954\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 83 year old man presented to his primary care physician with worsening dysphagia, initially to solids and now to liquids. His medical problems include hypertension treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , chronic obstructive pulmonary disease treated with inhaled steroids and bronchodilators, and long history of heartburn self-treated with over the counter antacids. His weight has been trending down and he has lost 16 lbs over the past two months. He denies fevers, nausea, vomiting, abdominal pain, or odynophagia. An upper endoscopy (",
"    <a class=\"graphic graphic_picture graphicRef77175 graphicRef77666 \" href=\"UTD.htm?22/27/22962\">",
"     picture 5A-B",
"    </a>",
"    ) with biopsies (",
"    <a class=\"graphic graphic_picture graphicRef56220 \" href=\"UTD.htm?33/10/33957\">",
"     picture 6",
"    </a>",
"    ) was performed. An endoscopic ultrasound showed the following (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69981 \" href=\"UTD.htm?4/28/4544\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evaluation revealed metastatic disease. The patient refused chemotherapy or radiation therapy. Endoscopic palliation therapy was performed (",
"    <a class=\"graphic graphic_picture graphicRef70138 \" href=\"UTD.htm?29/4/29775\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61261 \" href=\"UTD.htm?37/28/38350\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EOSINOPHILIC ESOPHAGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 25 year old male was referred for evaluation of increased frequency of intermittent episodes of dysphagia to solids. The first episode was three years ago. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow revealed multiple concentric rings in the proximal and mid esophagus giving it the appearance of a trachea (",
"    <a class=\"graphic graphic_picture graphicRef73447 \" href=\"UTD.htm?32/27/33214\">",
"     picture 8",
"    </a>",
"    ), which were also seen on endoscopy (",
"    <a class=\"graphic graphic_picture graphicRef50566 \" href=\"UTD.htm?31/2/31791\">",
"     picture 9",
"    </a>",
"    ). Biopsies were obtained in the proximal, mid and distal esophagus (",
"    <a class=\"graphic graphic_picture graphicRef70915 \" href=\"UTD.htm?31/10/31910\">",
"     picture 10",
"    </a>",
"    ). Because of persistent symptoms despite medical therapy, the patient underwent esophageal dilation, which was complicated with a deep esophageal tear (",
"    <a class=\"graphic graphic_picture graphicRef50953 \" href=\"UTD.htm?33/59/34750\">",
"     picture 11",
"    </a>",
"    ). Dilation should be performed extremely cautiously in patients with eosinophilic esophagitis because of an increased risk of perforation. Deep mucosal tears can occur without noting resistance after passing a dilator or upper endoscope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BARRETT'S ESOPHAGUS WITH LOW GRADE DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43 year old male with no significant past medical history was referred for the evaluation of worsening heartburn. He denies any dysphagia, odynophagia, weight loss or any other constitutional symptom. An upper endoscopy with biopsies was performed (",
"    <a class=\"graphic graphic_picture graphicRef63343 \" href=\"UTD.htm?10/57/11167\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52496 \" href=\"UTD.htm?22/40/23172\">",
"     picture 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BARRETT'S ESOPHAGUS WITH HIGH GRADE DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 59 year old male with no significant past medical history was referred for the evaluation of worsening heartburn. He denies any dysphagia, odynophagia, weight loss, or any other constitutional symptom. An upper endoscopy with biopsies was performed (",
"    <a class=\"graphic graphic_picture graphicRef61537 \" href=\"UTD.htm?32/39/33406\">",
"     picture 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80215 \" href=\"UTD.htm?34/52/35652\">",
"     picture 15",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 63 year old woman with a long history of tobacco use underwent an upper endoscopy for the evaluation of a positive fecal occult blood test, iron deficiency anemia, 15 lb weight loss over a three month period and progressive dysphagia to solids. The patient has no other medical problems. She denies fevers, nausea, vomiting, or abdominal pain. Endoscopic evaluation with multiple biopsies revealed the following (",
"    <a class=\"graphic graphic_picture graphicRef82670 \" href=\"UTD.htm?40/9/41118\">",
"     picture 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60051 \" href=\"UTD.htm?27/33/28181\">",
"     picture 17",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ESOPHAGITIS MIMICKING SHORT-SEGMENT BARRETT'S ESOPHAGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43 year old woman underwent an upper endoscopy for the evaluation of longstanding heartburn and regurgitation. The patient has no medical history and denies any fever, vomiting, or changes in weight. An upper endoscopy with biopsies showed the following (",
"    <a class=\"graphic graphic_picture graphicRef55838 \" href=\"UTD.htm?3/40/3727\">",
"     picture 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58307 graphicRef59215 \" href=\"UTD.htm?1/63/2040\">",
"     picture 19A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FOOD IMPACTION FROM A SCHATZKI RING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43 year old man with a long history of heartburn treated with over the counter antacids, presented to the emergency department soon after eating a hot dog with the complaint of \"having the hot dog stuck in my chest\" and inability to swallow his own saliva. The patient recalls that bread and meat sometimes pass slowly requiring him to take sips of water. An urgent upper endoscopy was performed in the emergency department, which revealed a distal esophageal ring (Schatzki ring) that was ulcerated (",
"    <a class=\"graphic graphic_picture graphicRef60342 graphicRef61768 \" href=\"UTD.htm?32/10/32928\">",
"     picture 20A-B",
"    </a>",
"    ). The patient was discharged home on a soft solid diet, a proton pump inhibitor with a scheduled upper endoscopy for possible treatment in two weeks. The ring was successfully dilated with a balloon (",
"    <a class=\"graphic graphic_picture graphicRef66882 graphicRef75853 graphicRef82313 \" href=\"UTD.htm?32/26/33188\">",
"     picture 21A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link\">",
"     \"Ingested foreign bodies and food impactions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CANDIDA ESOPHAGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24 year old male with AIDS underwent an upper endoscopy for the evaluation of substernal chest pain and a five day history of severe and worsening odynophagia. Endoscopy revealed candida esophagitis (",
"    <a class=\"graphic graphic_picture graphicRef65075 \" href=\"UTD.htm?9/43/9919\">",
"     picture 22",
"    </a>",
"    ), which was confirmed by cytology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOREIGN BODY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 49 year old man with past medical history significant for schizophrenia presented to the emergency department with chest and lower abdominal pain after \"accidentally swallowing his necklace\". Chest and abdominal imaging were obtained to assess the location of the foreign body and rule out perforation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78823 \" href=\"UTD.htm?21/57/22416\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An upper endoscopy was performed during which two coins, a cigarette butt, and a necklace with large gold cross were extracted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link\">",
"     \"Ingested foreign bodies and food impactions in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2249 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11124=[""].join("\n");
var outline_f10_55_11124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PILL ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLYCOGEN ACANTHOSIS AND BARRETT'S ESOPHAGUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESOPHAGEAL ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EOSINOPHILIC ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BARRETT'S ESOPHAGUS WITH LOW GRADE DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BARRETT'S ESOPHAGUS WITH HIGH GRADE DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ESOPHAGEAL SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ESOPHAGITIS MIMICKING SHORT-SEGMENT BARRETT'S ESOPHAGUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FOOD IMPACTION FROM A SCHATZKI RING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CANDIDA ESOPHAGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOREIGN BODY",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2249|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/28/4544\" title=\"diagnostic image 1\">",
"      Esophageal adenocarcinoma EUS CPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/28/38350\" title=\"diagnostic image 2\">",
"      Fluoroscopic view of self-expanding stent CPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/57/22416\" title=\"diagnostic image 3\">",
"      Esophageal foreign body CPC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2249|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/0/12303\" title=\"picture 1A\">",
"      Pill esophagitis CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/2/37934\" title=\"picture 1B\">",
"      Pill esophagitis II CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/57/34718\" title=\"picture 2\">",
"      Glycogen acanthosis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16001\" title=\"picture 3\">",
"      Glycogen acanthosis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/58/1954\" title=\"picture 4\">",
"      Intestinal metaplasia of the distal esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/16/8463\" title=\"picture 5A\">",
"      Esophageal adenocarcinoma endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/60/18383\" title=\"picture 5B\">",
"      Esophageal adenocarcinoma retroflexed CPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/10/33957\" title=\"picture 6\">",
"      Esophageal adenocarcinoma CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/4/29775\" title=\"picture 7\">",
"      Self expanding stent CPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/27/33214\" title=\"picture 8\">",
"      Eosinophilic esophagitis barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/2/31791\" title=\"picture 9\">",
"      Eosinophilic esophagitis rings CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/10/31910\" title=\"picture 10\">",
"      Eosinophilic esophagitis CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/59/34750\" title=\"picture 11\">",
"      Eosinophilic esophagitis mucosal tear post-dilation Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/57/11167\" title=\"picture 12\">",
"      Barretts esophagus CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/40/23172\" title=\"picture 13\">",
"      Barretts esophagus with low grade dysplasia Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/39/33406\" title=\"picture 14\">",
"      Barretts esophagus with high grade dysplasia CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/52/35652\" title=\"picture 15\">",
"      Barretts esophagus with high grade dysplasia CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/9/41118\" title=\"picture 16\">",
"      Squamous cell carcinoma of the distal esophagus Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/33/28181\" title=\"picture 17\">",
"      Squamous cell carcinoma esophagus Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/40/3727\" title=\"picture 18\">",
"      Esophageal erythema Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/8/8324\" title=\"picture 19A\">",
"      Carditis CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/49/23313\" title=\"picture 19B\">",
"      Barretts esophagus CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/15/30974\" title=\"picture 20A\">",
"      Food impaction CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/26/32174\" title=\"picture 20B\">",
"      Schatzki ring ulcerated Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/21/37214\" title=\"picture 21A\">",
"      Schatzki ring healed CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/10/5295\" title=\"picture 21B\">",
"      Endoscopy showing Schatzki ring dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/49/2847\" title=\"picture 21C\">",
"      Schatzki ring following balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/43/9919\" title=\"picture 22\">",
"      Candida esophagitis CPC Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=related_link\">",
"      Ingested foreign bodies and food impactions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11125="Normal urinary voiding";
var content_f10_55_11125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Coordination of the central and peripheral nervous systems for normal urinary voiding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The coordination of the central and peripheral nervous systems during bladder filling and voiding required for normal urinary continence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11125=[""].join("\n");
var outline_f10_55_11125=null;
var title_f10_55_11126="Buspirone: Pediatric drug information";
var content_f10_55_11126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Buspirone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"    see \"Buspirone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21540?source=see_link\">",
"    see \"Buspirone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Buspirone&reg;;",
"     </li>",
"     <li>",
"      BuSpar&reg;;",
"     </li>",
"     <li>",
"      Bustab&reg;;",
"     </li>",
"     <li>",
"      Dom-Buspirone;",
"     </li>",
"     <li>",
"      Novo-Buspirone;",
"     </li>",
"     <li>",
"      Nu-Buspirone;",
"     </li>",
"     <li>",
"      PMS-Buspirone;",
"     </li>",
"     <li>",
"      Riva-Buspirone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"      see \"Buspirone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents: Anxiety disorders: Limited information is available; dose is not well established. One pilot study of 15 children, 6-14 years of age (mean 10 years), with mixed anxiety disorders, used initial doses of 5 mg daily; doses were individualized with increases in increments of 5 mg/day every week as needed to a maximum dose of 20 mg/day divided into 2 doses; the mean dose required: 18.6 mg/day (Simeon, 1994). Some authors (Carrey, 1996 and Kutcher, 1992), based on their clinical experience, recommend higher doses (eg, 15-30 mg/day in 2 divided doses). An open-label study in 25 prepubertal inpatients (mean age: 8 &plusmn; 1.8 years; range: 5-11 years) with anxiety symptoms and moderately aggressive behavior used initial doses of 5 mg daily; doses were titrated upwards (over 3 weeks) by 5-10 mg every 3 days to a maximum dose of 50 mg/day; doses &gt;5 mg/day were administered in 2 divided doses/day; buspirone was discontinued in 25% of the children due to increased aggression and agitation or euphoric mania; mean optimal dose (n=19): 28 mg/day; range: 10-50 mg/day; median: 30 mg/day (Pfeffer, 1997). Two placebo-controlled 6-week trials in children and adolescents (n=559; age: 6-17 years) with generalized anxiety disorder studied doses of 7.5-30 mg twice daily (15-60 mg/day); no significant differences between buspirone and placebo with respect to generalized anxiety disorder symptoms were observed (see package insert).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 7.5 mg twice daily; increase in increments of 5 mg/day every 2-3 days as needed to a maximum of 60 mg/day; usual dose: 20-30 mg/day in 2 or 3 divided doses;",
"     <b>",
"      Note:",
"     </b>",
"     For patients receiving concomitant therapy with cytochrome P450 CYP3A4 inhibitors, a lower dose of buspirone is recommended (eg, 2.5 mg twice daily for patients receiving erythromycin; 2.5 mg daily for patients receiving itraconazole or nefazodone); with further dosage adjustments based on clinical assessment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients with impaired renal function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe renal impairment not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Patients with impaired hepatic function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe hepatic impairment not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer in a consistent manner in relation to food (ie, either always with food or always without food); may administer with food to decrease GI upset; use caution if administered with grapefruit juice; avoid large amounts of grapefruit juice",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 25&deg;C (77&deg;F). Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of anxiety disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       BusPIRone may be confused with buPROPion",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F143344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anger, confusion, dizziness, dream disturbance, drowsiness, excitement, headache, hostility, lightheadedness, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Incoordination, musculoskeletal pain, numbness, paresthesia, tremor. weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Akathisia, alcohol abuse, allergic reaction, alopecia, ALT increased, amenorrhea, angioedema, anorexia, AST increased, ataxia, bleeding disorder, bradycardia, bruising, cardiomyopathy, claustrophobia, cogwheel rigidity, conjunctivitis, CVA, dyskinesia, dystonia, edema, enuresis, eosinophilia, epistaxis, EPS, extrapyramidal symptoms, galactorrhea, hallucination, heart failure, hyper-/hypotension, hyperventilation, irritable colon, leukopenia, memory impairment, menstrual irregularity, MI, ocular pressure increased, parkinsonism, personality disorders, photophobia, PID, psychosis, rectal bleeding, restless leg syndrome, seizure, serotonin syndrome, slow reaction time, slurred speech, suicidal ideation, syncope, thrombocytopenia, thyroid abnormality, transaminase increases, visual disturbances (tunnel vision)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to buspirone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal dysfunction; use in severe hepatic or renal impairment is not recommended. Buspirone does not prevent or treat withdrawal from benzodiazepines or sedative/hypnotic drugs; if substituting buspirone for these agents, gradually withdraw the other drug(s) prior to initiating buspirone. Buspirone possesses a low potential for cognitive or motor impairment; however, until effects on an individual patient are known, patients should be warned to use caution when performing tasks which require mental alertness (eg, operating machinery or driving). Restlessness syndrome has been reported in a small number of patients; may be attributable to buspirone&rsquo;s antagonism of central dopamine receptors. Monitor for signs of any dopamine-related movement disorders (eg, dystonia, akathisia, pseudo-parkinsonism). Effectiveness of buspirone has not been established in pediatric patients; safety has been established in pediatric patients 6-17 years of age; no long-term safety or efficacy data is available in children.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use concurrently with MAO inhibitors or within 10 days of MAO inhibitors as significant increases in blood pressure may occur. Buspirone does not possess antipsychotic activity and should not be used in place of appropriate antipsychotic treatment; two pediatric cases of possible psychotic deterioration have been reported (Soni, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): BusPIRone may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of BusPIRone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: BusPIRone may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of BusPIRone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: BusPIRone may enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: BusPIRone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of BusPIRone. Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: BusPIRone may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may delay oral absorption, decrease the first-pass metabolism effect and increase oral bioavailability; grapefruit juice may greatly increase buspirone concentrations",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5628102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status, signs and symptoms of anxiety, liver and renal function; signs of dopamine-related movement disorders (eg, dystonia, akathisia, pseudo-parkinsonism).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases the spontaneous firing of serotonin-containing neurons in the CNS by selectively binding to and acting as agonist at presynaptic CNS serotonin 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     A receptors; possesses partial agonist activity (mixed agonist/antagonist) at postsynaptic 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     A receptors; does not bind to benzodiazepine-GABA receptors; binds to dopamine",
"     <sub>",
"      2",
"     </sub>",
"     receptors; may have other effects on other neurotransmitter systems; buspirone is &ldquo;anxiolytic-select&rdquo; and does not possess the anticonvulsant, muscle relaxant, or sedative effects of the benzodiazepines; little potential for abuse, tolerance, or withdrawal reactions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 3-4 weeks, up to 4-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete, but bioavailability is limited by extensive first-pass effect; only 1.5% to 13% (mean 4%) of the oral dose reaches the systemic circulation unchanged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 5.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver by oxidation (by cytochrome P450 isoenzyme CYP3A4) to several metabolites including 1-pyrimidinyl piperazine (about",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     as active as buspirone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: Mean: 2-3 hours; increased with renal or liver dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 40-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 29% to 63% excreted in urine (primarily as metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21540?source=see_link\">",
"      see \"Buspirone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and large amounts of grapefruit juice; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not appropriate for &ldquo;as needed&rdquo; (prn) use or for brief, situational anxiety; buspirone is equipotent to diazepam on a milligram to milligram basis in the treatment of anxiety; however, unlike diazepam, the onset of buspirone is delayed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carrey NJ, Wiggins DM, and Milin RP, &ldquo;Pharmacological Treatment of Psychiatric Disorders in Children and Adolescents,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 51(5):750-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/8861545 /pubmed\" id=\"8861545 \" target=\"_blank\">",
"        8861545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gammans RE, Mayol RF, and LaBudde JA, \"Metabolism and Disposition of Buspirone,\"",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1986, 80(3B):41-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/3515929/pubmed\" id=\"3515929\" target=\"_blank\">",
"        3515929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanna GL, Feibusch EL, and Albright KJ, &ldquo;Buspirone Treatment of Anxiety, Associated With Pharyngeal Dysphagia in a Four-Year Old,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(2):137-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/9334898/pubmed\" id=\"9334898\" target=\"_blank\">",
"        9334898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kutcher SP, Reiter S, Gardner DM, et al, &ldquo;The Pharmacotherapy of Anxiety Disorders in Children and Adolescents,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):41-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/1549548/pubmed\" id=\"1549548\" target=\"_blank\">",
"        1549548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer CR, Jiang H, and Domeshek LJ, &ldquo;Buspirone Treatment of Psychiatrically Hospitalized Prepubertal Children With Symptoms of Anxiety and Moderately Severe Aggression,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(3):145-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/9466232/pubmed\" id=\"9466232\" target=\"_blank\">",
"        9466232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG, Knott VJ, DuBois C, et al, &ldquo;Buspirone Therapy of Mixed Anxiety Disorders in Childhood and Adolescence: A Pilot Study,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1994, 4(3):159-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soni P and Weintraub AL, &ldquo;Buspirone-Associated Mental Status Changes,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1992, 31(6):1098-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/55/11126/abstract-text/1429411/pubmed\" id=\"1429411\" target=\"_blank\">",
"        1429411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13102 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11126=[""].join("\n");
var outline_f10_55_11126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051430\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051423\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143271\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143257\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051434\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051426\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051433\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143344\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051422\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051421\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143331\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051441\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5628102\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051429\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051420\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051436\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051437\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051428\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051439\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=related_link\">",
"      Buspirone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21540?source=related_link\">",
"      Buspirone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11127="Assessment of optic disc B";
var content_f10_55_11127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Assessment of the optic disc in healthy and glaucomatous eyes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top row shows findings in normal eyes and the bottow row findings in glaucomatous eyes. C: Scanning laser polarimetry: retinal nerve fibre layer thickness is reduced inferotemporally and superonasally. D: Confocal scanning laser ophthalmoscopy: neuroretinal rim area is within normal limits (ticks) in healthy eye but reduced in inferior and superonasal regions (crosses) in glaucomatous eye. E: Standard automated perimetry: normal blind spot and superior scotomas (arrows) in glaucoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Weinreb, RN, Khaw, PT. Primary open- angle glaucoma. Lancet 2004; 363:1711. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11127=[""].join("\n");
var outline_f10_55_11127=null;
var title_f10_55_11128="Diagnosis and evaluation of osteoporosis in postmenopausal women";
var content_f10_55_11128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and evaluation of osteoporosis in postmenopausal women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11128/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/55/11128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The World Health Organization has defined diagnostic thresholds for low bone mass and osteoporosis based upon bone mineral density (BMD) measurements compared with a young adult reference population (T-score).",
"   </p>",
"   <p>",
"    The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    age. The initial evaluation includes a history to assess for clinical risk factors for fracture and to evaluate for other conditions that contribute to bone loss, a physical examination, and basic laboratory tests. There are many coexisting medical conditions that contribute to bone loss. Thus, evaluation for alternative causes of bone loss to detect potentially reversible causes should be considered in those with abnormal initial findings. In addition, low BMD Z-scores (age-matched comparison) identify individuals requiring further evaluation for secondary causes of osteoporosis.",
"   </p>",
"   <p>",
"    Early diagnosis and quantification of bone loss and fracture risk have become more important because of the availability of therapies that can slow or even reverse the progression of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and evaluation of osteoporosis in postmenopausal women will be reviewed here. Identification of individuals for bone density testing and osteoporosis in premenopausal women are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis has no clinical manifestations until there is a fracture. This is an important fact, since many patients with achy hips or feet assume that their complaints are due to osteoporosis. This is unlikely to be true in the absence of fracture. In comparison, pain is common in osteomalacia in the absence of fractures or other bone deformities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vertebral fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral fracture is the most common clinical manifestation of osteoporosis. Most of these fractures (about two-thirds) are asymptomatic; they are diagnosed as an incidental finding on chest or abdominal x-ray. The clinical manifestations of symptomatic vertebral fracture, including height loss, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=see_link\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip fractures are relatively common in osteoporosis, affecting 15 percent of women and five percent of men by 80 years of age. Subchondral insufficiency fractures of the femoral head, which may lead to a rapid loss of cartilage space and eventual destructive secondary osteoarthritis, have also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, distal radius fractures (Colles fractures) may occur. Colles fractures are more common in women shortly after menopause, whereas the risk of hip fracture rises exponentially with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Increased risk of subsequent fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of a fracture is an important risk factor for a subsequent fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In women who have a vertebral fracture, approximately 19 percent will have another fracture in the next year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/3\">",
"     3",
"    </a>",
"    ]. A meta-analysis of 11 cohorts (15,259 men and 44,902 women) showed that a previous fracture was associated with an increased risk of any fracture compared with those without a prior fracture (RR 1.86, 95% CI 1.75-1.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, the majority of patients with vertebral, hip, and distal radius fractures do not receive evaluation and treatment for underlying osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, these patients frequently suffer additional fractures. Thus, individuals with a history of fracture are a high-risk group that require additional evaluation and treatment. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Medical intervention after fracture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is characterized by low bone mass, microarchitectural disruption and skeletal fragility, resulting in decreased bone strength and an increased risk of fracture. Decreased bone strength is related to many factors other than bone mineral density, including rates of bone formation and resorption (turnover), bone geometry (size and shape of bone), and microarchitecture (",
"    <a class=\"graphic graphic_picture graphicRef73327 \" href=\"UTD.htm?39/55/40818\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Assessment of microarchitecture requires bone biopsy, which is not routinely used in clinical practice. Therefore, bone mineral density (BMD) assessment is the gold standard to diagnose osteoporosis. However, a clinical diagnosis of osteoporosis may be made in the presence of a fragility fracture, without BMD measurement. As an example, a 75-year-old woman who sustained a vertebral fracture while bending likely has osteoporosis if the history, physical examination, laboratory tests, and plain x-rays do not suggest another diagnosis. BMD is helpful, on the other hand, when the circumstances surrounding the fracture are uncertain (traumatic or nontraumatic).",
"   </p>",
"   <p>",
"    Identification of individuals for bone density testing is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link&amp;anchor=H13#H13\">",
"     \"Screening for osteoporosis\", section on 'Candidates for BMD testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone mineral density definition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     T-score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) established a classification of BMD according the standard deviation (SD) difference between a patient's BMD and that of a young-adult reference population (T-score) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/8\">",
"     8",
"    </a>",
"    ]. A BMD T-score that is 2.5 standard deviations (SD) or more below the young-adult mean BMD is defined as osteoporosis, provided that other causes of low BMD have been ruled out (such as osteomalacia). A T-score that is 1 to 2.5 SD below the young-adult mean is termed osteopenia or low bone mass. Normal bone density is defined as a value within one standard deviation of the mean value in the young adult reference population (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"UTD.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Z-score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Z-score is a comparison of the patient's BMD to an age-matched population. A Z-score of -2.0 or lower is considered below the expected range for age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, the presence of Z-score values more than two standard deviations below the mean should prompt careful scrutiny for coexisting problems (eg, glucocorticoid therapy or alcoholism) that can contribute to osteoporosis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Low Z-scores'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Applicability of WHO criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO thresholds were chosen based upon fracture risk in postmenopausal Caucasian women. Similar diagnostic threshold values for men are less well defined, although for any given BMD, the age-adjusted fracture risk is similar in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/10\">",
"     10",
"    </a>",
"    ]. The International Society for Clinical Densitometry (ISCD) has made recommendations for the application of the WHO classification in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, the ISCD advises that the WHO criteria be used in postmenopausal women and in men age 50 and older, but not in premenopausal women or men under age 50 because the relationship between BMD and fracture risk is not the same in younger women and men.",
"   </p>",
"   <p>",
"    The WHO classification should not be used in children (male or female under age 20), and a diagnosis of osteoporosis cannot be made in a child based on densitometric criteria alone. Z-scores, not T-scores, should be used, since it is not appropriate to compare the BMD of someone who has not yet achieved peak bone mass to an adult who has. However, there are few well-established standardized reference databases for calculating Z-scores in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Method of BMD measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different methods are available to measure bone density. Dual energy x-ray absorptiometry (DXA) gives an accurate and precise estimate of bone mineral density (BMD). Thus, in clinical practice DXA is the technology used for diagnostic classification. Detailed information about DXA is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .) Other methods of measuring BMD for fracture risk assessment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H6#H6\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Methods of measurement of BMD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Site of measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all studies, the risk for most fractures is inversely proportional to bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/4,13-20\">",
"     4,13-20",
"    </a>",
"    ]. Some studies suggest that the risk for fracture at a particular site is best estimated by measuring bone density at that site [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Other studies, however, have found that measurement of BMD at any site predicts fracture risk at all sites equally well [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/25\">",
"     25",
"    </a>",
"    ]. The reference standard for diagnostic purposes is DXA at the hip (femoral neck or total hip) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the preferred site for measurement of bone density and the number of sites to measure are debatable, and may vary according to the clinical situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H16#H16\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Skeletal site to measure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for osteoporosis\", section on 'Skeletal site to measure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend DXA measurements of the spine and hip because fractures at these sites have the greatest impact on patients' health. Measurement of hip BMD also has the highest predictive value for hip fracture. In addition, if pharmacologic therapy is planned, measurement of spine BMD is useful as it shows less variability and can detect responses to therapy earlier than hip BMD. We make the diagnosis according to the lowest T-score measured.",
"   </p>",
"   <p>",
"    Interference from osteophytes and vascular calcifications on the spine measurement are common in aging women and interfere with the assessment of BMD at this site. In this setting, measurement of hip BMD alone is sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bone turnover markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the use of bone turnover markers (BTMs) in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents, their role in the care of individual patients is not well established. Potential roles of BTMs in clinical practice include prediction of fracture risk, monitoring response to therapy, and as an aid in selection of drug for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/27\">",
"     27",
"    </a>",
"    ]. It is not clear which specific BTM is most useful for specific clinical situations. Biologic and laboratory variability in BTM values have confounded their widespread use in clinical practice. We do not recommend measurements of markers of bone turnover for routine diagnostic purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased bone mass can occur because peak bone mass is low, bone resorption is excessive, or bone formation during remodeling is decreased. All three processes are likely to contribute, in varying degrees, to osteoporosis in individual patients. Most postmenopausal women with osteoporosis, however, have either age or estrogen deficiency-related bone loss due primarily to excessive bone resorption.",
"   </p>",
"   <p>",
"    The goal of the evaluation is to exclude secondary causes of low bone mass, such as osteomalacia, hyperthyroidism, and hyperparathyroidism, and to detect potentially remediable causes or other contributing factors to osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/28\">",
"     28",
"    </a>",
"    ]. The causes of secondary osteoporosis are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"UTD.htm?35/45/36573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Low bone mineral density may also be seen in conjunction with renal osteodystrophy in patients with decreased kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. It is difficult to distinguish low bone density due to osteoporosis from low bone density due to any of the components of chronic kidney disease metabolic bone disease. The distinction may be made biochemically in most cases, but may sometimes require bone biopsy. The diagnosis, evaluation, and management of osteoporosis in patients with chronic kidney disease and the diagnosis and management of renal osteodystrophy and secondary hyperparathyroidism are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37178?source=see_link\">",
"     \"Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation typically begins with a history, physical examination, and basic biochemical testing. Most of the conditions causing osteoporosis can be excluded with a careful history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"UTD.htm?35/45/36573\">",
"     table 2",
"    </a>",
"    ). Lifestyle factors that contribute to bone loss, including smoking, excessive alcohol, physical inactivity, and poor nutrition, should be addressed. Height and weight should be measured.",
"   </p>",
"   <p>",
"    Laboratory evaluation may help to diagnose secondary causes of osteoporosis such as renal or liver disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome or subclinical hypercortisolism, early menopause, celiac disease and other forms of malabsorption, idiopathic hypercalciuria, or rarely, connective tissue disorders (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"UTD.htm?35/45/36573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest that postmenopausal women with low BMD (T-score below -2.5)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragility fracture have the following basic tests (",
"    <a class=\"graphic graphic_table graphicRef62821 \" href=\"UTD.htm?1/57/1948\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biochemistry profile (especially calcium, phosphorous, albumin, total protein, creatinine, liver enzymes, including alkaline phosphatase, electrolytes)",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Urinary calcium excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Low Z-scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more extensive evaluation should be undertaken in patients who have low Z-scores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11128/abstract/36\">",
"     36",
"    </a>",
"    ]. The presence of values more than two standard deviations below the mean for age-matched normal subjects (Z-score) should prompt careful scrutiny for coexisting problems (eg, glucocorticoid therapy, malabsorption, hyperparathyroidism) that can contribute to osteoporosis (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"UTD.htm?35/45/36573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have abnormalities on the initial laboratory testing or who have suspicious findings on history and physical examination may also require additional laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef62821 \" href=\"UTD.htm?1/57/1948\">",
"     table 3",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer or multiple myeloma should be considered in patients who also have hypercalcemia, otherwise unexplained anemia, weight loss, or proteinuria. Measurement of serum and urine protein electrophoresis would be indicated in this case. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum PTH should be measured in patients with hypercalcemia, hypercalciuria, a history of renal stones, or osteopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A woman with unexplained anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low vitamin D and urinary calcium excretion should be tested for celiac disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary cortisol excretion should be measured if Cushing's syndrome is suspected and in patients with unexplained osteoporosis and vertebral fracture, since patients with subclinical hypercortisolism (mild hypercortisolism without clinical manifestations of Cushing's syndrome) are also at risk for low BMD and fractures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Bone loss'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H18#H18\">",
"       \"The adrenal incidentaloma\", section on 'Subclinical Cushing's syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a silent disease until fracture occurs. Complications of fractures include pain, deformity, disability, and loss of height.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is defined as low bone mass with microarchitectural disruption, resulting in increased skeletal fragility and fracture. Although bone strength is comprised of many components, bone mineral density (BMD) is measured most frequently in clinical practice. The WHO has established diagnostic thresholds for low bone mass and osteoporosis based upon BMD measurements of the hip (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"UTD.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A DXA T-score &le;-2.5 is consistent with osteoporosis, whereas a T-score between -1.0 and -2.5 is osteopenia. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Bone mineral density definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All postmenopausal women with osteoporosis (BMD T-score below -2.5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragility fracture) should have a history, physical examination, and basic laboratory evaluation. Initial laboratory studies should include a CBC, biochemistry profile, 25-hydroxyvitamin D, and assessment of urinary calcium excretion. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The need for additional laboratory evaluation depends upon the initial evaluation and Z-score (",
"    <a class=\"graphic graphic_table graphicRef62821 \" href=\"UTD.htm?1/57/1948\">",
"     table 3",
"    </a>",
"    ). Women who have abnormalities on initial laboratory testing, suspicious findings on history and physical examination suggesting a secondary cause of osteoporosis, or Z-scores &le; -2.0 may require additional evaluation for these secondary causes (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"UTD.htm?35/45/36573\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Low Z-scores'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Additional evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of osteoporosis in postmenopausal women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/1\">",
"      Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/2\">",
"      Yamamoto T, Bullough PG. The role of subchondral insufficiency fracture in rapid destruction of the hip joint: a preliminary report. Arthritis Rheum 2000; 43:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/3\">",
"      Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/4\">",
"      Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/5\">",
"      Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/6\">",
"      Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/7\">",
"      Neuner JM, Zimmer JK, Hamel MB. Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 2003; 51:483.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva 1994. file://whqlibdoc.who.int/trs/WHO_TRS_843.pdf (Accessed on March 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/9\">",
"      Binkley N, Bilezikian JP, Kendler DL, et al. Summary of the International Society For Clinical Densitometry 2005 Position Development Conference. J Bone Miner Res 2007; 22:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/10\">",
"      Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/11\">",
"      Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/12\">",
"      Kalkwarf HJ, Zemel BS, Gilsanz V, et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007; 92:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/13\">",
"      De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/14\">",
"      Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/15\">",
"      Kelly TL, Slovik DM, Schoenfeld DA, Neer RM. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. J Clin Endocrinol Metab 1988; 67:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/16\">",
"      Yamada M, Ito M, Hayashi K, et al. Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture. AJR Am J Roentgenol 1994; 163:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/17\">",
"      Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/18\">",
"      Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/19\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/20\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/21\">",
"      Melton, LJ III, Atkinson, EJ, O'Fallon, WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/22\">",
"      Eastell, R, Wahner, HW, O'Fallon, WM, et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 1989; 83:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/23\">",
"      Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/24\">",
"      Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/25\">",
"      Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/26\">",
"      Kanis JA, Gl&uuml;er CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/27\">",
"      Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005; 21:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/28\">",
"      Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/29\">",
"      Lob&atilde;o R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004; 62:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/30\">",
"      Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/31\">",
"      Moe S, Dr&uuml;eke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/32\">",
"      Lamberg-Allardt CJ, Outila TA, K&auml;rkkainen MU, et al. Vitamin D deficiency and bone health in healthy adults in Finland: could this be a concern in other parts of Europe? J Bone Miner Res 2001; 16:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/33\">",
"      Glerup H, Mikkelsen K, Poulsen L, et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000; 247:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/34\">",
"      Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/35\">",
"      Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87:4431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11128/abstract/36\">",
"      Lewiecki EM, Watts NB, McClung MR, et al. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 2004; 89:3651.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2035 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11128=[""].join("\n");
var outline_f10_55_11128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vertebral fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Increased risk of subsequent fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone mineral density definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - T-score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Z-score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Applicability of WHO criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Method of BMD measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Site of measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bone turnover markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Low Z-scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2035|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/55/40818\" title=\"picture 1\">",
"      Age related trabecular loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/28/11723\" title=\"table 1\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/45/36573\" title=\"table 2\">",
"      Secondary causes osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/57/1948\" title=\"table 3\">",
"      Laboratory evaluation postmenopausal osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37178?source=related_link\">",
"      Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11129="Neurologic manifestations of rheumatoid arthritis";
var content_f10_55_11129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic manifestations of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Monica L Piecyk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11129/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11129/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/55/11129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is associated with various nonarticular manifestations, including severe neurologic abnormalities. A variety of pathogenic mechanisms are responsible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid synovitis and pannus may compress or invade adjacent structures (including the spinal cord and peripheral nerves), resulting in myelopathy, radiculopathy, and entrapment neuropathies.",
"     </li>",
"     <li>",
"      Rheumatoid vasculitis may cause ischemia, infarction, or bleeding; these may ultimately result in transient ischemic attacks (TIA), stroke, quadriplegia, or paraparesis. With peripheral nervous system involvement due to vasculitis, there may be multiple nerve dysfunction (mononeuritis multiplex) or a more indolent polyneuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The introduction of newer medications in recent decades, along with more aggressive and effective strategies for the treatment of RA, appears to have reduced the frequency with which some of the neurologic manifestations of RA are observed.",
"   </p>",
"   <p>",
"    Because both neurologic and muscular disorders may present with weakness, muscular diseases that occur in association with RA will also be reviewed here. Other nonarticular and non-neurologic problems associated with RA are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the central nervous system (CNS) due to RA include cervical myelopathy, vasculitis, rheumatoid nodules located within the CNS, meningitis, organic brain syndrome, and (rarely) progressive multifocal leukoencephalopathy. Stroke also occurs with increased frequency, but the basis for this association is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cervical myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical myelopathy (cervical myeloradiculopathy) resulting from atlantoaxial subluxation, atlantoaxial impaction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subaxial subluxation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Central nervous system vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS vasculitis is rare in patients with RA, with the literature generally consisting of case reports of intracranial arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. CNS lesions are also infrequent in patients with systemic rheumatoid vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting manifestations of CNS vasculitis include seizures, dementia, cranial nerve palsies, strokes, encephalopathy, intracerebral or subarachnoid hemorrhage, and myelopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain biopsy is the most specific diagnostic test. Cerebral angiography and magnetic resonance angiogram also may be helpful but are less specific. However, some evidence suggests that MRI abnormalities among symptomatic patients with RA cannot be ascribed to vasculitis alone. One study, for example, evaluated the incidence of hyperintense white matter lesions with magnetic resonance imaging, findings suggestive of vasculitis, in 33 asymptomatic patients with RA and 48 control individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/11\">",
"     11",
"    </a>",
"    ]. There was no significant difference in the number of such lesions between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of patients with RA and CNS vasculitis is similar to that for patients with isolated CNS vasculitis. This includes high-dose glucocorticoids and cytotoxic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules have been reported rarely in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/12\">",
"     12",
"    </a>",
"    ]. Extradural nodules in the spinal canal may cause nerve root compression, spinal cord compression, and spinal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rheumatoid nodules of the cerebral leptomeninges and within the choroid plexus also have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/6,15-18\">",
"     6,15-18",
"    </a>",
"    ]. Neurologic signs and symptoms in these patients have not always correlated with the anatomic location of the nodules; in many cases, there was coexistent CNS pathology.",
"   </p>",
"   <p>",
"    Most patients with CNS nodules have severe erosive joint disease, other extraarticular features, and high titer rheumatoid factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/13,16,18\">",
"     13,16,18",
"    </a>",
"    ]. In reported cases, the diagnosis of CNS rheumatoid nodules was made pathologically, either at surgery or autopsy.",
"   </p>",
"   <p>",
"    Surgical decompression should be performed if a rheumatoid nodule is compressing a vital structure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid meningitis consists of an inflammatory infiltrate of the meninges without distinct rheumatoid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/12,19,20\">",
"     12,19,20",
"    </a>",
"    ]. Most patients have long-standing, seropositive disease. Symptoms may include altered mental status, fever, headaches, seizures, cranial nerve dysfunction, and hemiparesis or paraparesis. Elevated cerebrospinal fluid levels of protein are the most common abnormality, but pleocytosis and depressed glucose also are described. In the majority of reported patients, the diagnosis of rheumatoid meningitis was only made at autopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Organic brain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of organic brain syndrome (OBS), including confusion, memory loss, and seizures, have been described in six RA patients being treated with no or low dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/21\">",
"     21",
"    </a>",
"    ]. However, it is unknown whether the OBS was actually due to RA. Four were treated with high dose steroid therapy. All six patients, including those who were observed without therapy, improved within one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Progressive multifocal leukoencephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of progressive multifocal leukoencephalopathy (PML), which is associated with the polyoma JC virus, is increased in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for RA, but the absolute risk is very small. PML was reported in two patients with RA prior to the use of biologic disease modifying antirheumatic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/22\">",
"     22",
"    </a>",
"    ]. A case was also reported in a patient with RA on rituximab and other immunosuppressive therapies, who was also treated for a malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/23\">",
"     23",
"    </a>",
"    ]. In patients with RA treated with rituximab, at least four cases of PML have been reported to regulatory agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/24\">",
"     24",
"    </a>",
"    ]. The estimated absolute risk of PML is one case per 25,000 patients with RA treated with rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/25\">",
"     25",
"    </a>",
"    ]. In an observational study using a nationwide inpatient sample database in the United States, the rate of PML in hospitalized patients with RA was estimated at 0.4 per 100,000 discharges, twice the rate in the background population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H16#H16\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Hypogammaglobulinemia and infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperviscosity syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperviscosity may cause symptoms similar to those seen in patients with Waldenstr&ouml;m&rsquo;s macroglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/27\">",
"     27",
"    </a>",
"    ]. The clinical manifestations of hyperviscosity include headache, visual changes, vertigo, tinnitus, hearing loss, and cognitive dysfunction. This syndrome is discussed in more detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of stroke in RA, especially ischemic stroke. A 2008 meta-analysis, involving over 111,758 patients in 24 studies, found a significant increase in the risk of death from cerebrovascular accidents in patients with RA, compared with the general population (weighted-pooled summary estimate of standardized mortality ratios of 1.52, 95% CI 1.40-1.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/28\">",
"     28",
"    </a>",
"    ]. Significant heterogeneity, however, was found between the studies analyzed, and some studies have not shown stroke to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/29\">",
"     29",
"    </a>",
"    ]. The following are examples of three large individual studies that have addressed the risk of stroke in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The magnitude of this effect was illustrated in a nested case-control analyses within a longitudinal data bank of 16,990 patients with RA compared with 5140 patients with noninflammatory rheumatic disease, 226 first strokes, of which 59 were ischemic, occurred in the RA patients (odds ratio 1.64 for all first strokes, 95% CI 1.16-2.30, and 2.66 for ischemic strokes, 95% CI 1.24-5.70) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/30\">",
"       30",
"      </a>",
"      ]. Risk factors for ischemic stroke included severity of RA, hypertension, myocardial infarction and low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use, but not diabetes, smoking, exercise, or body mass index. Treatment with rofecoxib and possibly antecedent treatment with glucocorticoids were other possible risk factors.",
"     </li>",
"     <li>",
"      A significant increase in stroke was also noted in a population based study of 25,385 Canadian adults with RA, which evaluated the incidence of cardiovascular events (including myocardial infarction, stroke, or cardiovascular death) compared to age- and sex-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/31\">",
"       31",
"      </a>",
"      ]. The patients with RA had a small but significant absolute increase in stroke risk (2.4 per 1000 person-years, rate ratio 1.9, 95% CI 1.7-2.1). The absolute increase in cardiovascular events in RA patients was much greater in those over age 65.",
"     </li>",
"     <li>",
"      A nationwide Danish cohort study involving 18,247 patients with RA followed for a median of 4.8 years identified 718 strokes in patients with RA, representing a significant absolute increase in stroke risk compared with the general population (1.9 per 1000 person-years, with an adjusted incidence rate ratio of 1.32, 95% CI 1.22-1.42) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/32\">",
"       32",
"      </a>",
"      ]. This study also demonstrated an increased risk of atrial fibrillation in patients with RA, but the degree to which this contributed to stroke risk was not determined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H187567760#H187567760\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with RA also have an increased risk of coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10631?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PERIPHERAL NERVOUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression neuropathies are the most common neurologic manifestation of RA. Sensory and motor dysfunction may also occur due to noncompressive neuropathies and myopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Compression or entrapment neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entrapment neuropathies are diagnosed in approximately one-half of RA patients with severe peripheral disease and subcutaneous nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/33\">",
"     33",
"    </a>",
"    ]. Joint deformities and inflamed synovium, ligaments, or tendon sheaths may compress peripheral nerves that are in close proximity to joints or bursae. There is no correlation between compression neuropathies and gender, duration of RA, functional class, the presence of other extraarticular disease, seropositivity, or the level of acute phase reactants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) is probably the most common neurologic manifestation of RA and can occur at any time during the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/2,33,35,36\">",
"     2,33,35,36",
"    </a>",
"    ]. In different series, CTS occurred in 23 to 69 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/34,37-39\">",
"     34,37-39",
"    </a>",
"    ]. The probable cause of CTS is finger-flexor tenosynovitis, since these tendons also pass through the carpal tunnel.",
"   </p>",
"   <p>",
"    Symptoms, findings, neurodiagnostic testing, and differential diagnosis of CTS in patients with RA is similar to that for other patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=see_link\">",
"     \"Etiology of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conservative and surgical therapies are also similar and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=see_link\">",
"     \"Surgery for carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tarsal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tarsal tunnel syndrome, which is less common than CTS, is due to compression of the posterior tibial nerve as it passes near the medial malleolus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/33,40,41\">",
"     33,40,41",
"    </a>",
"    ]. Tarsal tunnel syndrome may result from tenosynovitis, inflammation of the flexor retinaculum, valgus deformities, adjacent bone fracture or dislocation, or posttraumatic edema and fibrosis. Symptoms include paresthesia and pain in the sole of the foot and the first through third toes. Findings of atrophy and weakness of the intrinsic foot muscles occur with more advanced disease. From 5 to 25 percent of RA patients have electrophysiologic abnormalities characteristic of tarsal tunnel syndrome, although not all of these patients are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of the tarsal tunnel syndrome in patients with RA is similar to the approach for other patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other compression neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although unusual, compression of other peripheral nerves has been reported in patients with RA. Affected nerves include the anterior and posterior interosseous, ulnar, common peroneal, and tibial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/33,35,36,40,41,45,46\">",
"     33,35,36,40,41,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An entrapment neuropathy and symptomatic cervical spine disease with nerve root compression may present concurrently and is termed the \"double crush\" syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The common peroneal and tibial nerves may be compressed by a popliteal cyst. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H16#H16\">",
"       \"Evaluation of the active adult patient with knee pain\", section on 'Popliteal cyst'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"       \"Popliteal (Baker's) cyst\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment of compression neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical management involves treatment of the underlying disease process. Additional modalities include splints, antiinflammatory medications, and local corticosteroid injections. Surgical decompression is indicated if motor deficits or denervation are present, or if sensory symptoms worsen despite adequate nonsurgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/43,46\">",
"     43,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Noncompression neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic abnormalities detected by nerve conduction studies (NCS) and electromyographic (EMG) studies are reportedly more common in patients with RA than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/47\">",
"     47",
"    </a>",
"    ]. Distal sensory neuropathy and sensorimotor neuropathy have been reported in one to eighteen percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/39\">",
"     39",
"    </a>",
"    ]. Vasculopathy and vasculitis have been implicated in the pathogenesis of these neuropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/9,36,45,48-50\">",
"     9,36,45,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Distal sensory neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral sensory polyneuropathy, which typically presents in a slowly progressive fashion, has the following additional clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms may be difficult to distinguish from those due to arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/36,48\">",
"       36,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symmetric paresthesias and burning sensations tend to be worse in the feet than in the hands [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/36,48,51\">",
"       36,48,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vibratory, pinprick, and light touch sensation are decreased, while proprioception is spared.",
"     </li>",
"     <li>",
"      Reflexes may be lost, and both sensory and motor nerve conduction studies may be abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/48,50\">",
"       48,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of 25 patients, neuropathy usually developed after the arthritis, and there was no relation between duration of RA and neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/48\">",
"     48",
"    </a>",
"    ]. Studies employing sural nerve biopsy reveal mild proliferative endarteritis or normal vasculature with segmental demyelination and remyelination with areas of axonal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. There is mild loss of predominantly large myelinated fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/35,48\">",
"     35,48",
"    </a>",
"    ]. The yield of biopsy may be low given the mild pathological changes and patchy distribution of lesions.",
"   </p>",
"   <p>",
"    Overall, distal sensory neuropathy has a good prognosis. It is uncommon for patients to progress to a more severe neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/45,48\">",
"     45,48",
"    </a>",
"    ]. In most patients, the severity of neuropathy is not altered with steroid therapy; 75 percent of patients recover partially or completely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Combined sensorimotor neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined sensorimotor neuropathy is associated with long duration seropositive, nodular RA, male gender, other extraarticular involvement, systemic constitutional symptoms, and other signs of vasculitis including palpable purpura, livedo reticularis, skin ulcerations, nailfold and digital infarcts, and Raynaud phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/9,23,36,45,48,50-52\">",
"     9,23,36,45,48,50-52",
"    </a>",
"    ]. High rheumatoid factor titers, a polyclonal increase in immunoglobulins, and low complement levels are also common.",
"   </p>",
"   <p>",
"    Combined sensorimotor neuropathy is more severe and presents more acutely than distal sensory neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/36,48\">",
"     36,48",
"    </a>",
"    ]. Symptoms include significant asymmetric pain and paresthesias. Weakness may develop within hours to days of the initial onset of symptoms. Wrist and foot drops are most common, and deep tendon reflexes are decreased or absent. Asymptomatic sensorimotor neuropathy may be more common, being reported in one series in",
"    <span class=\"nowrap\">",
"     26/40",
"    </span>",
"    patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/53\">",
"     53",
"    </a>",
"    ]. Mononeuritis multiplex or a polyneuropathy have been reported. Electrophysiologic studies demonstrate axonal degeneration or severe demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. These findings are suggestive of nerve damage due to vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations relate to vasculitic neuropathy seen specifically in patients with RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial pathology of affected peripheral nerves includes fibrinoid necrosis of the media with infiltration by polymorphonuclear leukocytes, eosinophils, and mononuclear cells. Perivascular infiltration with mononuclear cells, intimal proliferation with minimal cellular infiltrates,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrosis also can be observed [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/50\">",
"       50",
"      </a>",
"      ]. Vasculitis of the epineural arteries results in vessel ischemia with resulting axonal degeneration and neuronal demyelination [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/40,50\">",
"       40,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The arteritis may be immune-complex mediated. Sural nerve examination has demonstrated IgG, IgM, complement, and fibrin depositions in areas of acute necrotizing arteritis, while these deposits are usually absent in vessels without acute inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no standard treatment regimen for this neuropathy. Patients have been treated as for immune complex-mediated necrotizing vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/40\">",
"     40",
"    </a>",
"    ]. Both corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , in oral doses and intravenous pulses, have been used. Small case series and case reports document successful treatment of rheumatoid vasculitis with tumor necrosis factor inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    .) There is no convincing evidence that steroids are helpful or that antimalarials and gold alter the course of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/36,48\">",
"     36,48",
"    </a>",
"    ]. Plasmapheresis has been used in refractory cases but without great success [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined sensorimotor neuropathy has a poor prognosis, with most patients progressively worsening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/23,36,45,48\">",
"     23,36,45,48",
"    </a>",
"    ]. Death may result from visceral disease or immunosuppressive therapy related infections. Most individuals who improve have residual sensory and motor deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Autonomic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased incidence of autonomic neuropathy, as determined by abnormal cardiovascular reflexes, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular disorders are frequently found in RA. Muscle weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrophy have been observed in approximately one third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/55\">",
"     55",
"    </a>",
"    ]. Neuromuscular disorders include myopathy and myositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathic processes, which are subdivided into disuse or denervation atrophy, must be distinguished from a muscular dystrophy, such as myopathy and weakness due to corticosteroid use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Disuse atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness and wasting with disuse atrophy results from pain due to synovitis. Muscle biopsy reveals type II fiber atrophy; there is no muscle inflammation, necrosis, regeneration, or vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/49,55-57\">",
"     49,55-57",
"    </a>",
"    ]. Effective treatment requires control of joint inflammation and reduction in pain, which is followed by a strengthening exercise program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Denervation atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motor nerve demyelination and degeneration due to angiopathic neuropathy, such as mononeuritis multiplex, can lead to muscle fiber atrophy, necrosis, and regeneration, with minimal muscle inflammation on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/49,55\">",
"     49,55",
"    </a>",
"    ]. Treatment for weakness due to ischemia or infarction of peripheral nerve is directed at control of vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    .) If vasculitis is arrested, strength may recover slowly as remyelination and axonal regeneration occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Muscular dystrophy-like myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscular dystrophy-like myopathy in those with RA is similar to muscular dystrophy both clinically and pathologically. There is loss of muscle tissue, replacement by adipose tissue, fiber caliber variations, and fibrosis without inflammatory infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/49\">",
"     49",
"    </a>",
"    ]. Motor innervation is not disturbed. This may represent late chronic myositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Glucocorticoid-induced myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid-induced or steroid myopathy is characterized by proximal muscle weakness without significant serum muscle enzyme elevations. Muscle biopsy reveals type II fiber atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Gradual reduction in the glucocorticoid dose and a muscle strengthening rehabilitation program are the mainstays of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With myofiber necrosis and regeneration, there is focal or diffuse infiltration of lymphocytes, plasma cells, and mononuclear cells into the endomysium, perimysium, and perivascular areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/49,55,56,59\">",
"     49,55,56,59",
"    </a>",
"    ]. Since it may be impossible to distinguish myositis in RA from idiopathic polymyositis, this process may represent an overlap syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/2,49,55\">",
"     2,49,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One author has suggested that the pathologic abnormalities in rheumatoid myositis are less severe and more patchy than those of polymyositis, and that RA patients tend to respond to lower",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses than do polymyositis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/56\">",
"     56",
"    </a>",
"    ]. In this study, rheumatoid myositis was also associated with elevated serum creatine kinase levels, reflecting muscle fiber damage, and with disproportionately elevated erythrocyte sedimentation rates for the mild degree of synovitis.",
"   </p>",
"   <p>",
"    Treatment of myositis complicating RA is similar to the therapy of idiopathic polymyositis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA may rarely be complicated by secondary amyloidosis, which may result in abnormalities in both the central and peripheral nervous systems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/2\">",
"     2",
"    </a>",
"    ]. Amyloid deposits have been reported in brain arterioles in four patients with RA and CNS vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Peripheral neuropathy can also result from secondary amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications utilized to treat RA are another major cause of neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11129/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs may result in headaches, drowsiness, and aseptic meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids can cause myopathy, depression, psychosis, and benign intracranial hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimalarials, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , can cause dizziness, headache, tinnitus, seizures, and neuromyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gold therapy can be complicated by peripheral neuropathy, cranial nerve palsies, and Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"       \"Major side effects of gold\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      can cause headaches and impair the ability to concentrate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      reportedly cause headaches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"       \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      is associated with peripheral neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"       \"Leflunomide in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Agents that interfere with the action of tumor necrosis factor alpha (anti-TNF therapies) may increase the risk of demyelinating disorders of the CNS. Progressive multifocal leukoencephalopathy and peripheral neuropathy also have occurred in patients treated with anti-TNF therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Progressive multifocal leukoencephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1689845\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic abnormalities associated with rheumatoid arthritis (RA) can result from compression by or infiltration of the spinal cord or nerves by rheumatoid synovitis and pannus and from rheumatoid vasculitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders of the central nervous system (CNS) due to RA include cervical myelopathy, vasculitis, rheumatoid nodules located within the CNS, meningitis, organic brain syndrome, and, rarely, progressive multifocal leukoencephalopathy. Therapy of patients with RA and CNS vasculitis is similar to that for patients with isolated CNS vasculitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stroke, particularly ischemic stroke, occurs with increased frequency, but the basis for this association is not well-understood. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compression neuropathies are the most common neurologic manifestation of RA. The most common entrapment neuropathy in RA is carpal tunnel syndrome, which is most likely due to finger-flexor tenosynovitis. Other syndromes due to nerve compression or entrapment include tarsal tunnel syndrome, due to compression of the posterior tibial nerve near the medial malleolus; syndromes affecting the anterior and posterior interosseous, ulnar, common peroneal, and tibial nerves; cervical nerve root compression; and common peroneal and tibial nerve compression from popliteal cysts. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Compression or entrapment neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noncompressive neuropathies include both distal sensory neuropathy, which is usually slowly progressive, and sensorimotor neuropathy, which may have a more acute presentation and which occurs in more severely affected patients with seropositive nodular disease and other extraarticular manifestations. These conditions may result from vasculopathy and vasculitis. An increased incidence of autonomic neuropathy may also be present in patients with RA. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Noncompression neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuromuscular disorders are frequent in RA and may result in muscle weakness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atrophy. These disorders include myopathy due to disuse or to denervation, which may be confused with myopathy due to glucocorticoids, and myositis, which is similar to polymyositis and which may represent part of an overlap syndrome. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Neuromuscular disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the medications used to treat RA, including nonsteroidal antiinflammatory drugs, glucocorticoids, and both traditional and biologic disease-modifying antirheumatic drugs, are associated with neurologic complications. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/1\">",
"      Beck DO, Corbett JJ. Seizures due to central nervous system rheumatoid meningovasculitis. Neurology 1983; 33:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/2\">",
"      Kim RC, Collins GH. The neuropathology of rheumatoid disease. Hum Pathol 1981; 12:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/3\">",
"      Mandybur TI. Cerebral amyloid angiopathy: possible relationship to rheumatoid vasculitis. Neurology 1979; 29:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/4\">",
"      Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol 1975; 32:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/5\">",
"      Singleton JD, West SG, Reddy VV, Rak KM. Cerebral vasculitis complicating rheumatoid arthritis. South Med J 1995; 88:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/6\">",
"      STEINER JW, GELBLOOM AJ. Intracranial manifestations in two cases of systemic rheumatoid disease. Arthritis Rheum 1959; 2:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/7\">",
"      Watson P. Intracranial hemorrhage with vasculitis in rheumatoid arthritis. Arch Neurol 1979; 36:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/8\">",
"      Watson P, Fekete J, Deck J. Central nervous system vasculitis in rheumatoid arthritis. Can J Neurol Sci 1977; 4:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/9\">",
"      Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/10\">",
"      Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 1987; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/11\">",
"      Bekkelund SI, Pierre-Jerome C, Husby G, Mellgren SI. Quantitative cerebral MR in rheumatoid arthritis. AJNR Am J Neuroradiol 1995; 16:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/12\">",
"      Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/13\">",
"      Friedman H. Intraspinal rheumatoid nodule causing nerve root compression. Case report. J Neurosurg 1970; 32:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/14\">",
"      Hauge T, Magnaes B, L&oslash;ken AC, de Graaf AS. Treatment of rheumatoid pachymeningitis involving the entire thoracic region. Scand J Rheumatol 1978; 7:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/15\">",
"      Contin JU, Oka M. Unusual cardiac, pulmonary and meningeal involvement in rheumatoid arthritis. Report of a case. Dis Chest 1966; 49:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/16\">",
"      Jackson CG, Chess RL, Ward JR. A case of rheumatoid nodule formation within the central nervous system and review of the literature. J Rheumatol 1984; 11:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/17\">",
"      Sunter JP. Rheumatoid disease with involvement of the leptomeninges presenting as symptomatic epilepsy. Beitr Pathol 1977; 161:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/18\">",
"      Kim RC, Collins GH, Parisi JE. Rheumatoid nodule formation within the choroid plexus. Report of a second case. Arch Pathol Lab Med 1982; 106:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/19\">",
"      Chowdhry V, Kumar N, Lachance DH, et al. An unusual presentation of rheumatoid meningitis. J Neuroimaging 2005; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/20\">",
"      Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology 2007; 68:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/21\">",
"      Gupta VP, Ehrlich GE. Organic brain syndrome in rheumatoid arthritis following corticosteroid withdrawal. Arthritis Rheum 1976; 19:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/22\">",
"      Nakano KK. Neurologic complications of rheumatoid arthritis. Orthop Clin North Am 1975; 6:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/23\">",
"      Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/24\">",
"      Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 Suppl 2:i2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/25\">",
"      Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/26\">",
"      Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60:3761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/27\">",
"      Zakzook SI, Yunus MB, Mulconrey DS. Hyperviscosity syndrome in rheumatoid arthritis with Felty's syndrome: case report and review of the literature. Clin Rheumatol 2002; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/28\">",
"      Avi&ntilde;a-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/29\">",
"      Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/30\">",
"      Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/31\">",
"      Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/32\">",
"      Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344:e1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/33\">",
"      Nakano KK. The entrapment neuropathies of rheumatoid arthritis. Orthop Clin North Am 1975; 6:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/34\">",
"      Herbison GJ, Teng C, Martin JH, Ditunno JF Jr. Carpal tunnel syndrome in rheumatoid arthritis. Am J Phys Med 1973; 52:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/35\">",
"      Brick JE, Brick JF. Neurologic manifestations of rheumatologic disease. Neurol Clin 1989; 7:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/36\">",
"      PALLIS CA, SCOTT JT. PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS. Br Med J 1965; 1:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/37\">",
"      Barnes CG, Currey HL. Carpal tunnel syndrome in rheumatoid arthritis. A clinical and electrodiagnostic survey. Ann Rheum Dis 1967; 26:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/38\">",
"      Chamberlain MA, Corbett M. Carpal tunnel syndrome in early rheumatoid arthritis. Ann Rheum Dis 1970; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/39\">",
"      Fleming A, Dodman S, Crown JM, Corbett M. Extra-articular features in early rheumatoid disease. Br Med J 1976; 1:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/40\">",
"      Chang DJ, Paget SA. Neurologic complications of rheumatoid arthritis. Rheum Dis Clin North Am 1993; 19:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/41\">",
"      Hurd ER. Extraarticular manifestations of rheumatoid arthritis. Semin Arthritis Rheum 1979; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/42\">",
"      Baylan SP, Paik SW, Barnert AL, et al. Prevalence of the tarsal tunnel syndrome in rheumatoid arthritis. Rheumatol Rehabil 1981; 20:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/43\">",
"      Grabois M, Puentes J, Lidsky M. Tarsal tunnel syndrome in rheumatoid arthritis. Arch Phys Med Rehabil 1981; 62:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/44\">",
"      McGuigan L, Burke D, Fleming A. Tarsal tunnel syndrome and peripheral neuropathy in rheumatoid disease. Ann Rheum Dis 1983; 42:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/45\">",
"      FERGUSON RH, SLOCUMB CH. Peripheral neuropathy in rheumatoid arthritis. Bull Rheum Dis 1961; 11:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/46\">",
"      White SH, Goodfellow JW, Mowat A. Posterior interosseous nerve palsy in rheumatoid arthritis. J Bone Joint Surg Br 1988; 70:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/47\">",
"      Bekkelund SI, Torbergsen T, Husby G, Mellgren SI. Myopathy and neuropathy in rheumatoid arthritis. A quantitative controlled electromyographic study. J Rheumatol 1999; 26:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/48\">",
"      Chamberlain MA, Bruckner FE. Rheumatoid neuropathy. Clinical and electrophysiological features. Ann Rheum Dis 1970; 29:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/49\">",
"      Haslock DI, Wright V, Harriman DG. Neuromuscular disorders in rheumatoid arthritis. A motor-point muscle biopsy study. Q J Med 1970; 39:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/50\">",
"      Weller RO, Bruckner FE, Chamberlain MA. Rheumatoid neuropathy: a histological and electrophysiological study. J Neurol Neurosurg Psychiatry 1970; 33:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/51\">",
"      Conn DL, McDuffie FC, Dyck PJ. Immunopathologic study of sural nerves in rheumatoid arthritis. Arthritis Rheum 1972; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/52\">",
"      Goldman JA, Casey HL, McIlwain H, et al. Limited plasmapheresis in rheumatoid arthritis with vasculitis. Arthritis Rheum 1979; 22:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/53\">",
"      Lanzillo B, Pappone N, Crisci C, et al. Subclinical peripheral nerve involvement in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/54\">",
"      Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J 1979; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/55\">",
"      Reza MJ, Verity MA. Neuromuscular manifestations of rheumatoid arthritis: A clinical and histomorphological analysis. Clin Rheum Dis 1977; 3:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/56\">",
"      Halla JT, Koopman WJ, Fallahi S, et al. Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum 1984; 27:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/57\">",
"      Haslock DI, Harriman DF, Wright V. Neuromuscular disorders associated with rheumatoid arthritis. Ann Rheum Dis 1970; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/58\">",
"      Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11129/abstract/59\">",
"      Wegelius O, Pasternack A, Kuhlb&auml;ck B. Muscular involvement in rheumatoid arthritis. Acta Rheumatol Scand 1969; 15:257.",
"     </a>",
"    </li>",
"    <li>",
"     Rheumatology, 2nd, Klippel JH, Dieppe PA (Eds), Mosby, Philadelphia 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7480 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11129=[""].join("\n");
var outline_f10_55_11129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1689845\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CENTRAL NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cervical myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Central nervous system vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Organic brain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Progressive multifocal leukoencephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperviscosity syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PERIPHERAL NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Compression or entrapment neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tarsal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other compression neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment of compression neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Noncompression neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Distal sensory neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Combined sensorimotor neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NEUROMUSCULAR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Disuse atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Denervation atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Muscular dystrophy-like myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Amyloid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1689845\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10631?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=related_link\">",
"      Surgery for carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11130="Cephalosporin allergy: Clinical manifestations and diagnosis";
var content_f10_55_11130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cephalosporin allergy: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11130/contributors\">",
"     Antonino Romano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11130/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/55/11130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/55/11130/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/55/11130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4382802\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporins are among the most commonly-used antibiotics in the treatment of routine infections, and their use is increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Cephalosporins can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with IgE-mediated allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the clinical manifestations, pathogenesis, and diagnosis of hypersensitivity reactions to cephalosporins. Issues of cross-reactivity between cephalosporins, penicillins, and related drugs, and the subsequent use of cephalosporins and related antibiotics in patients with cephalosporin or penicillin allergy, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=see_link\">",
"     \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518454020\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS, INCIDENCE, AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to cephalosporins may be divided as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions, which develop within one hour after administration",
"     </li>",
"     <li>",
"      Non-immediate reactions, which develop &gt;one hour after administration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification and pathogenesis of allergic drug reactions are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202204\">",
"    <span class=\"h2\">",
"     Immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate reactions are characterized by various combinations of flushing, urticaria, angioedema, rhinitis, bronchospasm, and anaphylactic shock. These reactions are classified as type I reactions in the Gel and Coombs system of immunologic reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ). Many immediate reactions involve urticaria or hives, which are intensely pruritic, erythematous, cutaneous plaques or papules. Urticarial lesions resolve over the course of hours without residual markings, and then reappear elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75230 \" href=\"UTD.htm?27/16/27905\">",
"     picture 2",
"    </a>",
"    ). When evaluating a drug reaction, the clinician should look for signs and symptoms of immediate reactions, such as urticaria, bronchospasm, or hypotension. Careful attention should be paid to the patient's skin, both at the time of evaluation and when recording the details of the reaction in the patient&rsquo;s medical record, since accurate and detailed information can greatly facilitate later diagnosis and management.",
"   </p>",
"   <p>",
"    Immediate, type I reactions occur in patients who have formed IgE antibodies against specific allergenic epitopes of a cephalosporin molecule (or a metabolite of the molecule, or the combination of the",
"    <span class=\"nowrap\">",
"     drug/metabolite",
"    </span>",
"    conjugated to serum proteins). If the patient with these antibodies receives the same drug again, the drug (or its metabolite, etc) reacts with IgE bound to the surface of mast cells and basophils and leads to the activation, degranulation, and release of vasoactive mediators from these cells. These mediators cause the signs and symptoms of IgE-mediated allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202211\">",
"    <span class=\"h3\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis, the most severe and dangerous form of IgE-mediated reactions, may present with a spectrum of possible signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ). Cephalosporin-induced anaphylaxis may be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anaphylactic reactions to cephalosporins are rare (frequency: 0.0001 to 0.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/5\">",
"     5",
"    </a>",
"    ], although an increasing number of such reactions have been reported in the last decade. Any cephalosporin can cause anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16-65\">",
"     16-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207320\">",
"    <span class=\"h4\">",
"     Possible allergens and cross-reactivity with penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may develop IgE antibodies against antigenic determinants that are unique to cephalosporins or to determinants that are shared with other beta-lactam drugs, particularly the penicillins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. The core structure of both penicillins and cephalosporins contains a four-membered beta-lactam ring. Patients may become sensitized to this core structure or to metabolites of it, or to one of the two antigenic side chain groups (R1 and R2) that are unique to cephalosporins (",
"    <a class=\"graphic graphic_figure graphicRef69298 \" href=\"UTD.htm?6/26/6573\">",
"     figure 1",
"    </a>",
"    ). The frequency with which people become sensitized to these different moieties is believed to be as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitization to structurally similar R1 side chain groups (most common)",
"     </li>",
"     <li>",
"      Sensitization to structurally similar R2 side chain groups (infrequent)",
"     </li>",
"     <li>",
"      Sensitization to the core beta-lactam ring or its metabolites (infrequent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following clinical observations have been made about patients with immediate reactions to a cephalosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/22,29,37,40\">",
"     22,29,37,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant percentage (ie, up to 37 percent in large studies) of patients who react to one cephalosporin will react to other cephalosporins.",
"     </li>",
"     <li>",
"      Most patients with immediate reactions to cephalosporins are allergic only to cephalosporins and",
"      <strong>",
"       not",
"      </strong>",
"      to penicillins. In one large European series, only 25 percent of 98 patients with immediate cephalosporin reactions had positive skin tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum specific IgE assays to penicillin reagents [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beyond these general statements, however, it is difficult to determine the overall importance of side chains in allergic reactions to cephalosporins because of the problems inherent in studying drug allergy. There are numerous studies in which positive in vitro tests or skin tests are obtained with cephalosporins that contain similar or identical side chains, but for obvious ethical reasons, most protocols do not challenge patients with positive tests to the drug in question. Thus, it is rarely known if these results translate into actual clinical cross-reactivity. Penicillin skin testing, which is far better validated than cephalosporin skin testing, illustrates this point. Among patients with positive skin tests to penicillin, 40 to 100 percent will react upon challenge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H22604340#H22604340\">",
"     \"Penicillin skin testing\", section on 'Interpretation of results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies by pharmacology investigators have grouped penicillins and cephalosporins according to side chain structures, although data to support the clinical relevance of these groupings is largely lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/71\">",
"     71",
"    </a>",
"    ]. The clinician must not falsely assume that because two cephalosporins have different side chain groups, that the patient will not react to both. Instead, caution is warranted, with assistance from an allergist in patients with severe past reactions.",
"   </p>",
"   <p>",
"    Issues of cross-reactivity among cephalosporins and between cephalosporins and penicillins, carbapenems, and monobactams are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=see_link\">",
"     \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382830\">",
"    <span class=\"h2\">",
"     Non-immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large percentage of cephalosporin reactions are non-immediate cutaneous reactions. These most often consist of maculopapular or morbilliform cutaneous eruptions, or delayed-onset",
"    <span class=\"nowrap\">",
"     urticaria/angioedema.",
"    </span>",
"    In a study concerning cutaneous adverse drug reactions, 290 of the 947 patients evaluated reported reactions to cephalosporins, most of which were maculopapular rashes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/72\">",
"     72",
"    </a>",
"    ]. In a pediatric series of 105 patients with non-immediate reactions to cephalosporins, 58 demonstrated urticaria, 29 had maculopapular rash, 13 had erythema, 8 had both urticaria and angioedema, and 8 had isolated edema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16\">",
"     16",
"    </a>",
"    ]. In another study of mostly adults, the same types of reactions were reported, although maculopapular rash was the most common presentation (39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of these non-immediate reactions seems to be heterogeneous and is not completely understood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical and immunological studies suggest that a type-IV (cell-mediated) pathogenic mechanism may be involved in some non-immediate reactions, such as maculopapular or bullous rashes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some non-immediate cutaneous reactions may not represent drug hypersensitivity at all, but may instead be manifestations of the underlying infection itself [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/75\">",
"       75",
"      </a>",
"      ]. Specifically, concomitant infection with certain viruses, such as those caused by human immunodeficiency virus (HIV), cytomegalovirus (CMV), human herpes virus 6 (HHV6) or Epstein-Barr virus (EBV), may predispose patients receiving cephalosporins to develop cutaneous reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most non-immediate cutaneous reactions will not recur with the next exposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the study of children described previously, subjects underwent allergy testing (for both immediate and non-immediate types of reactions) and 104 of the children had negative results [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16\">",
"       16",
"      </a>",
"      ]. Of these, 96 were challenged with the cephalosporin that caused the reaction in the past, and 94 had no recurrence of symptoms. The average time that had elapsed between the last cephalosporin exposure and evaluation in this study was eight months.",
"     </li>",
"     <li>",
"      In a similar study of 105 adults, subjects underwent a similar allergy evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"       73",
"      </a>",
"      ] and 98 had negative results. Of these, 86 patients agreed to be challenged with the cephalosporin that caused the reaction in the past, and none developed symptoms. The time elapsed between exposure and evaluation was 1 to 312 months (median 11 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382837\">",
"    <span class=\"h3\">",
"     Maculopapular rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maculopapular or morbilliform rashes are common adverse reactions to cephalosporins (",
"    <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"     picture 3",
"    </a>",
"    ). These are mostly mild and self-limited and are typically delayed in onset by several hours to days after the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,72,73\">",
"     16,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382844\">",
"    <span class=\"h3\">",
"     Delayed onset urticaria/angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema are other common presentations of a non-immediate cephalosporin reaction, in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,72,73\">",
"     16,72,73",
"    </a>",
"    ]. However, because urticaria and angioedema are also signs of type I hypersensitivity (which can progress to anaphylaxis with re-exposure), these patients should also be evaluated for IgE-mediated allergy and caution is warranted when managing a patient with past urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,73\">",
"     16,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the pediatric series of 105 patients mentioned above, 58 of 116 non-immediate reactions to cephalosporins in otherwise healthy children were urticarial eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features that help distinguish these reactions from IgE-mediated reactions include onset of symptoms that is delayed more than an hour after the last administered dose, and the absence of other signs or symptoms of anaphylaxis, such as bronchospasm or hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382851\">",
"    <span class=\"h3\">",
"     Other uncommon reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporins have been associated with other types of non-immediate hypersensitivity reactions, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum sickness-like reactions, which are most often reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"       cefaclor",
"      </a>",
"      use in children, may occur due to a genetic defect in metabolism of this specific drug [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Linear IgA bullous dermatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fixed drug eruptions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe exfoliative cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/80-82\">",
"       80-82",
"      </a>",
"      ] and erythroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/83\">",
"       83",
"      </a>",
"      ]. Patients with these severe reactions should never be exposed to the causative drug again. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated fever [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/84,85\">",
"       84,85",
"      </a>",
"      ], isolated eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/86,87\">",
"       86,87",
"      </a>",
"      ], or both in association with drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome (DiHS) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/88-91\">",
"       88-91",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H26#H26\">",
"       \"Drug allergy: Classification and clinical features\", section on 'Type IV Reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subsequent use of cephalosporins in patients with serum sickness-like reactions, drug fever, and other uncommon reactions is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=see_link&amp;anchor=H998984#H998984\">",
"     \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\", section on 'Past serum sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998584\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author of this topic and editors of UpToDate suggest the following regarding referral of patients to an allergy specialist (preferably with experience in drug allergy):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient with a severe, possibly IgE-mediated, immediate reaction to a cephalosporin should be advised to avoid all cephalosporins and penicillins and should be evaluated by an allergy specialist if these classes of antibiotics are likely to be required in the future. Such individuals may be able to receive other cephalosporins",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      penicillins safely, although this can only be determined through an allergy evaluation.",
"     </li>",
"     <li>",
"      Patients with immediate urticaria, angioedema, or both (but",
"      <strong>",
"       without",
"      </strong>",
"      other signs and symptoms of anaphylaxis) in response to a cephalosporin should be advised to avoid all cephalosporins and penicillins and should be evaluated by an allergy specialist if these classes of antibiotics are likely to be needed in the future. If referral is not feasible, then graded challenge with a cephalosporin",
"      <strong>",
"       other than the one that caused the reaction",
"      </strong>",
"      and with different side-chains is an alternative approach to management. (See",
"      <a class=\"local\" href=\"#H206045\">",
"       'Graded challenge (test dosing)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with non-immediate, morbilliform or maculopapular eruptions in response to a cephalosporin should avoid the culprit cephalosporin. In Europe, the patient can be referred to an allergist for evaluation of a delayed reaction. However, in the US, where these evaluations are rarely performed, referral would be indicated only if other cephalosporins are needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382858\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cephalosporin allergy is based upon the clinical history, physical exam (if signs or symptoms are still present), skin testing, and occasionally in vitro testing and challenge (when appropriate) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204407\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary aims of the clinical history are to assess what type of reaction the patient likely experienced in the past, and to detect severe drug reactions, such as anaphylaxis, or",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"    The history of a drug reaction should ascertain the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each exact agent reportedly associated with a reaction, and the indication for its use",
"     </li>",
"     <li>",
"      The signs and symptoms involved",
"     </li>",
"     <li>",
"      The dose and route of medication taken (if known)",
"     </li>",
"     <li>",
"      Other concurrent medications, especially if they were new or temporary",
"     </li>",
"     <li>",
"      The timing of onset of the reaction (both from the precipitating dose, as well as from the initiation of that course of therapy)",
"     </li>",
"     <li>",
"      Any treatment given and response to that treatment (including the duration of the reaction)",
"     </li>",
"     <li>",
"      Any prior or subsequent history of exposure to the same drug or structurally similar drugs, with or without reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205961\">",
"    <span class=\"h2\">",
"     Evaluation of immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with an immediate cephalosporin reaction is similar to that of patients with immediate penicillin reactions, with the following important differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross-reactivity among cephalosporins is not as extensive as among penicillins and most patients with past cephalosporin reactions can receive other cephalosporins safely. A main objective of evaluation is to determine whether a different, desired cephalosporin will be tolerated.",
"     </li>",
"     <li>",
"      Skin testing with cephalosporins is not as well validated as penicillin skin testing for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The allergenic determinants of cephalosporins have not been conclusively defined, unlike those for penicillins",
"     </li>",
"     <li>",
"      Reagents are not commercially available for testing to cephalosporin-protein conjugates",
"     </li>",
"     <li>",
"      The positive and negative predictive values of testing have not been fully established",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206010\">",
"    <span class=\"h3\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the limitations listed above, there are multiple reports of small numbers of patients with histories of immediate reactions to a specific cephalosporin that were confirmed with positive skin tests to the culprit drug, and in which the patient was successfully challenged with other beta-lactams (including first-, second-, and third-generation cephalosporins) to which skin testing was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/21,23,26,27,30,54,94-98\">",
"     21,23,26,27,30,54,94-98",
"    </a>",
"    ]. Thus, a negative skin test to a candidate cephalosporin in a patient with previous cephalosporin reactions provides some presumptive safety estimate, compared with other cephalosporins to which the patient had positive skin tests.",
"   </p>",
"   <p>",
"    A period of two to four weeks should be allowed between an immediate reaction and skin testing to the suspect drug, since skin testing may be falsely negative if performed too soon. However, positive results obtained during this period are still valid.",
"   </p>",
"   <p>",
"    Skin testing should include positive (histamine) and negative (saline) controls.",
"    <span class=\"nowrap\">",
"     Prick/puncture",
"    </span>",
"    technique is performed first. If",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    tests are negative, then intradermal testing should be performed next [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/92,93,99\">",
"     92,93,99",
"    </a>",
"    ]. A general discussion of skin testing techniques is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The author's approach to skin testing with cephalosporins is provided here. We suggest including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cephalosporin(s) that caused the reaction",
"     </li>",
"     <li>",
"      One or more alternative cephalosporins with dissimilar side chains, especially in the R1 position, that the patient could potentially receive instead (",
"      <a class=\"graphic graphic_figure graphicRef53755 \" href=\"UTD.htm?39/12/40132\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The classic penicillin reagents [",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"       penicilloyl-polylysine",
"      </a>",
"      (PPL), the minor determinant mixture (MDM), and benzylpenicillin] to detect patients who are sensitized to the core beta-lactam structure shared by penicillins and cephalosporins",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      to detect patients who are sensitized to the side chains in these common aminopenicillins, which are also present in some cephalosporins (",
"      <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Techniques for skin testing to penicillin are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cephalosporin solutions for skin testing can be prepared from injectable therapeutic preparations, if available. A range of concentrations have been used successfully:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A concentration of 2",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (in normal saline) was shown to be nonirritating in a group of 40 nonallergic control subjects for several injectable cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/25,37\">",
"       25,37",
"      </a>",
"      ]. This concentration was used for both epicutaneous (ie, prick) and intradermal testing [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,37,40\">",
"       16,37,40",
"      </a>",
"      ]. In another study by the author&rsquo;s group, skin testing with the aminocephalosporins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"       cefaclor",
"      </a>",
"      , and cefatrizine) was performed with concentrations of 2 and 20",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      after the higher concentration was shown to be nonirritating in 30 control subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"       73",
"      </a>",
"      ]. These are the concentrations used in the author&rsquo;s clinic.",
"     </li>",
"     <li>",
"      Another study demonstrated that a concentration of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , and 33",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , were nonirritating in at least 25 healthy adults [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 58 patients showed that concentrations of 20",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      were nonirritating [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with prior severe anaphylaxis to a cephalosporin, solutions for initial skin testing can be diluted 10- to 1000-fold further, to reduce the risk of inducing a systemic reaction.",
"   </p>",
"   <p>",
"    Testing solutions of penicillins and cephalosporins are prepared freshly on the day of testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,29,37\">",
"     16,29,37",
"    </a>",
"    ]. For injectable cephalosporins, the intravenous form is used. For noninjectable cephalosporins, the powder contained in capsules or obtained by removing with a scalpel the external layer of tablets is used. After weighing the powder, solutions are prepared under a laminar flow hood, as previously described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], and are sterilized by filtration through single-use devices (Minisart&reg; NML Syringe Filter, 0.20 &mu;m, Sartorius AG, Goettingen, Germany) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37\">",
"     37",
"    </a>",
"    ]. The author&rsquo;s approach is to spread testing over three separate days to allow for delayed reactions. Testing with penicillin reagents is performed on one day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    on another, and testing to cephalosporins on a third day [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,37\">",
"     16,37",
"    </a>",
"    ]. However, this may not be feasible in some settings, and the full panel of tests may not be clinically indicated in all situations. For example, if a patient developed hives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    but had no known adverse reaction to penicillin, and the clinician simply wanted to determine if it was safe to treat the patient with penicillins in the future, then it might be sufficient just to skin test with the classic penicillin reagents and with the selected penicillin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206017\">",
"    <span class=\"h4\">",
"     Positive results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive skin test (on the volar forearm) to a cephalosporin drug may be defined as a wheal &gt;3 mm in diameter, with surrounding erythema, that develops within 20 minutes of placement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37,103\">",
"     37,103",
"    </a>",
"    ]. If the skin test response is positive, it implies the presence of drug-specific IgE antibodies and potential clinical allergy. However, as with skin testing for most drugs, the positive predictive value has not been precisely defined because this would require administering the drug to large numbers of skin test-positive patients with no personal benefit to confirm that they are truly reactive; such testing would pose ethical issues and thus has not been done. Cephalosporins that yield positive skin tests should not be given except through a desensitization protocol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of skin testing with cephalosporins has been estimated in three European studies involving children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16\">",
"     16",
"    </a>",
"    ], both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/40\">",
"     40",
"    </a>",
"    ], and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37\">",
"     37",
"    </a>",
"    ] with histories of immediate reactions to these beta-lactams. Skin testing was positive in 72 percent",
"    <span class=\"nowrap\">",
"     (31/43),",
"    </span>",
"    31 percent",
"    <span class=\"nowrap\">",
"     (39/127),",
"    </span>",
"    and 70 percent",
"    <span class=\"nowrap\">",
"     (53/76)",
"    </span>",
"    of patients in these studies, respectively, although patients with positive test results were not challenged to confirm if these were true positives (for the ethical reasons mentioned previously). The rates of positive reactions in these studies are much higher than the rates obtained if penicillin allergic patients are tested with native penicillin. No comparable studies have been done on patient populations outside of Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998736\">",
"    <span class=\"h4\">",
"     Negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    and intradermal test responses are negative, it suggests that the patient does not have specific IgE antibodies to the cephalosporin in its native state. However, the patient could still have IgE antibodies against a metabolite or metabolite-protein complex, and the negative predictive value of cephalosporin skin testing is not well defined. Therefore, a negative result should not be interpreted as proof that allergy is not present.",
"   </p>",
"   <p>",
"    As an example, in a study of adult patients with immediate reactions to cephalosporins, 8 of 13 adults with negative tests agreed to undergo challenges with the suspect drug, and two patients reacted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206038\">",
"    <span class=\"h3\">",
"     In vitro assays for cephalosporin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro assays for cephalosporin-specific IgE are not commonly used because they are less sensitive than skin testing and not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37,93\">",
"     37,93",
"    </a>",
"    ]. Only a few studies have performed investigational assays for IgE to cephalosporins other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    in samples larger than 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/22,29,37,67,104,105\">",
"     22,29,37,67,104,105",
"    </a>",
"    ]. The only commercially available immunoassay is for cefaclor (ImmunoCAP, Phadia, Uppsala, Sweden).",
"   </p>",
"   <p>",
"    In some centers, a flow cytometric basophil activation tests (BAT) for drug allergy are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/106-110\">",
"     106-110",
"    </a>",
"    ]. This is not widely available in the United States, and additional comprehensive studies in large samples are required in order to further validate the technique and provide a definitive assessment of its sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206045\">",
"    <span class=\"h3\">",
"     Graded challenge (test dosing)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A graded challenge does not modify a patient&rsquo;s response to a drug, so patients who tolerate challenge prove that they are not allergic. Graded challenges often require experience to interpret properly because patients can develop non-specific or anxiety-related symptoms. As discussed previously, the specificity of skin testing appears to be sufficiently high that we do NOT recommend performing challenges with cephalosporins to which patients are skin-test positive. (See",
"    <a class=\"local\" href=\"#H206017\">",
"     'Positive results'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Graded challenges are usually performed for one of two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       To identify a safe alternative drug",
"      </strong>",
"      &mdash; The most common reason for performing a graded challenge is to confirm that a patient can safely receive an alternative cephalosporin (",
"      <strong>",
"       other than the culprit drug",
"      </strong>",
"      ) to which there is no evidence of allergy after evaluation.",
"      <br/>",
"      <br/>",
"      The starting dose for a graded challenge is usually",
"      <span class=\"nowrap\">",
"       1/100",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      of the full dose, depending on the severity and recentness of the reaction. Tenfold increasing doses are administered every 30 to 60 minutes until the full therapeutic dose is reached. A simple challenge for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      would be 5 mg, 50 mg, and 500 mg given orally at 60 minute intervals, using dilutions of a standard oral suspension, or the powder obtained from tablets. A lower starting dose should be used in patients with severe reactions. The cumulative dose must be adjusted for children or in subjects with kidney or liver disease.",
"     </li>",
"     <li>",
"      <strong>",
"       To prove or disprove allergy",
"      </strong>",
"      &mdash; Graded challenge with the",
"      <strong>",
"       culprit",
"      </strong>",
"      cephalosporin may be performed in selected patients with negative skin testing results, according to the recommendations of both the American and European guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]. This is done to confirm or disprove the presence of allergy with certainty.",
"      <br/>",
"      <br/>",
"      Patients who develop symptoms consistent with an IgE-mediated reaction during or shortly after the graded challenge (within a few hours of receiving the full dose), should be treated appropriately and should not receive further drug. These patients should be considered allergic to that agent and it should be avoided or, if critical, administered via a formal desensitization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206081\">",
"    <span class=\"h3\">",
"     Risk of resensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of immediate reactions to beta-lactams, negative skin-test results should be interpreted in light of the time elapsed since the subject&rsquo;s last exposure to the drug. In reports of patients with IgE-mediated hypersensitivity to cephalosporins, skin tests are more likely to be positive the less time has elapsed since the clinical reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,37,113\">",
"     16,37,113",
"    </a>",
"    ]. Therefore, in subjects with immediate reactions to cephalosporins who have negative skin tests when evaluated more than six months after their last reaction, the author performs challenges with suspected cephalosporins and, in case of negative responses, administers a full therapeutic course. In addition, the author retests such patients after four weeks to determine if there has been resensitization after previous loss of sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/37,92,93\">",
"     37,92,93",
"    </a>",
"    ]. Resensitization (diagnosed on the basis of renewed skin-test positivity) has been observed in a few patients retested about one month after either negative challenges (whether followed by a full therapeutic course or not), or after positive challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,37,113\">",
"     16,37,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, resensitization is possible, although the rate at which this occurs in not defined. As a result, we suggest that patients with severe, IgE-mediated reactions in past be retested before subsequent courses of treatment if they require the same cephalosporin (that caused the reaction) in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H208530\">",
"    <span class=\"h2\">",
"     Evaluation of non-immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manner in which non-immediate drug reactions are evaluated differs significantly between the US and Europe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In European centers, patients with non-immediate reactions are evaluated with both patch tests and delayed-reading of intradermal tests [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/92,114\">",
"       92,114",
"      </a>",
"      ]. These tests are negative in most patients. As an example, in a study of patients with cutaneous reactions to cephalosporins, patch testing with the implicated cephalosporin was positive in just 4 percent",
"      <span class=\"nowrap\">",
"       (12/290)",
"      </span>",
"      of non-immediate reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/72\">",
"       72",
"      </a>",
"      ]. In the aforementioned study by the author&rsquo;s group, only 5 of the 105 adults with histories of non-immediate reactions to cephalosporins presented positive responses to delayed-reading intradermal tests with the responsible compounds, three of whom were also patch-test positive [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"       73",
"      </a>",
"      ]. There are additional case reports of patients with maculopapular rashes in whom patch tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed-reading intradermal tests were positive [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73,115-120\">",
"       73,115-120",
"      </a>",
"      ]. Because the sensitivity of patch testing and delayed-reading of intradermal skin testing is low, provocation tests with the suspected cephalosporins, when appropriate, may be needed to establish the diagnosis when testing is positive [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/92,114\">",
"       92,114",
"      </a>",
"      ]. The negative predictive value of either patch testing or delayed-reading of intradermal skin testing appears to be high [",
"      <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/16,72,73\">",
"       16,72,73",
"      </a>",
"      ], although more work is needed. The timing with which these tests are performed does not appear to impact the results.",
"     </li>",
"     <li>",
"      In the United States, patch testing and delayed-reading intradermal tests are not widely performed. Instead, the most common approach in the US is to diagnose non-immediate reactions to cephalosporins based upon signs and symptoms. If the reaction involved hives or angioedema, the patient may be evaluated for IgE-mediated allergy to the cephalosporin that caused the reaction, as well as the cephalosporin that is needed in the immediate future. If the patient&rsquo;s past reaction did",
"      <strong>",
"       not",
"      </strong>",
"      involve hives or angioedema, then a graded challenge to the desired cephalosporin (generally not the same drug that caused the initial reaction, although the same drug can be used if it is superior for the treatment of a particular infection) can be performed. (See",
"      <a class=\"local\" href=\"#H206045\">",
"       'Graded challenge (test dosing)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89835615\">",
"    <span class=\"h3\">",
"     Challenges for non-immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For delayed or non-immediate types of reactions, challenge procedures are not standardized and different experts have distinct approaches. The optimal approach is not known, and the issues with such challenges are described in this section. The limitations of challenges should be explained to patients.",
"   </p>",
"   <p>",
"    In general, challenge protocols are based upon the time course of the patient's reaction and the pharmacology of the drug involved. The time between doses should be long enough that delayed symptoms have time to develop before the next higher dose is administered.",
"   </p>",
"   <p>",
"    The author&rsquo;s approach to challenging patients with past delayed reactions to cephalosporins is to give increasing doses at weekly intervals, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Day 1: Administer",
"      <span class=\"nowrap\">",
"       1/100",
"       <sup>",
"        th",
"       </sup>",
"      </span>",
"      of a usual dose",
"     </li>",
"     <li>",
"      Day 7: Administer",
"      <span class=\"nowrap\">",
"       1/10",
"       <sup>",
"        th",
"       </sup>",
"      </span>",
"      of a usual dose",
"     </li>",
"     <li>",
"      Day 14: Administer a full dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a negative result may not preclude a non-immediate reaction with full therapeutic treatment. Specifically, studies of penicillin reactions have documented that some delayed reactions only develop after several days of a full therapeutic dose, or in the presence of a concomitant viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Thus, there may be certain drug reactions that cannot be elicited with any challenge protocol and will only recur if the drug is used for therapy again in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare forms of non-immediate reactions, such as serum sickness or drug fever, are not diagnosed with any type of skin testing, because these tests do not provide clinically relevant information about these reactions, which are often related to the intensity and duration of treatment. Patients who experienced these types of reactions should not be given the same cephalosporins again unless under the supervision of a drug allergy specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=see_link&amp;anchor=H998984#H998984\">",
"     \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\", section on 'Past serum sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210967\">",
"    <span class=\"h1\">",
"     OPTIONS FOR SUBSEQUENT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with past reactions to a specific cephalosporin may require subsequent treatment with a different cephalosporin or a related antibiotic (eg, a penicillin, carbapenem, or monobactam). Approaches to these clinical scenarios are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=see_link\">",
"     \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211259\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF CEPHALOSPORIN ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporin allergy may be lost over time, although the phenomenon is not as well documented as it is with penicillin allergy and the rate of loss of sensitization is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?10/55/11130/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4382970\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of cephalosporins is increasing, and this class of antibiotics can cause a range of hypersensitivity reactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic drug reactions may be broadly divided into immediate reactions, which begin within one hour of administration, and non-immediate reactions, which begin after that time period. (See",
"      <a class=\"local\" href=\"#H518454020\">",
"       'Clinical manifestations, incidence, and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate reactions to cephalosporins are primarily IgE-mediated reactions, such as urticaria, angioedema, or anaphylaxis. (See",
"      <a class=\"local\" href=\"#H202204\">",
"       'Immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-immediate reactions include maculopapular rash, urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema that begin hours to days after administration, and rare reactions, such as serum sickness, Stevens-Johnson syndrome, drug fever, and drug-induced hypersensitivity syndrome. (See",
"      <a class=\"local\" href=\"#H4382830\">",
"       'Non-immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema can represent a non-immediate reaction or a mild IgE-mediated reaction. Because IgE-mediated reactions can progress to anaphylaxis, all patients with urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema, regardless of the timing, should undergo a careful evaluation for IgE-mediated allergy. (See",
"      <a class=\"local\" href=\"#H4382858\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H205961\">",
"       'Evaluation of immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of IgE mediated allergy to cephalosporins involves clinical history, skin testing to cephalosporins and penicillin determinants, and possibly graded challenge. (See",
"      <a class=\"local\" href=\"#H205961\">",
"       'Evaluation of immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms involved in most non-immediate reactions to cephalosporins are not completely understood. In the United States, these reactions are usually diagnosed clinically. European centers evaluate such patients with patch tests and delayed reading of intradermal tests (See",
"      <a class=\"local\" href=\"#H4382858\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H208530\">",
"       'Evaluation of non-immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/1\">",
"      McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/2\">",
"      Cars O, M&ouml;lstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/3\">",
"      Ferech M, Coenen S, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/4\">",
"      Norrby SR. Side effects of cephalosporins. Drugs 1987; 34 Suppl 2:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/5\">",
"      Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/6\">",
"      Romano A, Torres MJ, Namour F, et al. Immediate hypersensitivity to cephalosporins. Allergy 2002; 57 Suppl 72:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/7\">",
"      Madaan A, Li JT. Cephalosporin allergy. Immunol Allergy Clin North Am 2004; 24:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/8\">",
"      Gu&eacute;ant JL, Gu&eacute;ant-Rodriguez RM, Viola M, et al. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12:3335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/9\">",
"      Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/10\">",
"      Spruill FG, Minette LJ, Sturner WQ. Two surgical deaths associated with cephalothin. JAMA 1974; 229:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/11\">",
"      Hoffman DR, Hudson P, Carlyle SJ, Massello W 3rd. Three cases of fatal anaphylaxis to antibiotics in patients with prior histories of allergy to the drug. Ann Allergy 1989; 62:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/12\">",
"      Pumphrey RS, Davis S. Under-reporting of antibiotic anaphylaxis may put patients at risk. Lancet 1999; 353:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/13\">",
"      Trani N, Bonetti LR, Gualandri G, Barbolini G. Immediate anaphylactic death following antibiotics injection: splenic eosinophilia easily revealed by pagoda red stain. Forensic Sci Int 2008; 181:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/14\">",
"      Tsujikawa K, Kuwayama K, Miyaguchi H, et al. A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis. J Forensic Sci 2008; 53:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/15\">",
"      Riezzo I, Bello S, Neri M, et al. Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare. Allergy 2010; 65:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/16\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/17\">",
"      Thiella G, Bucci L, Agrati AM, Palmieri G. Nonfatal anaphylactic shock following an unusual sensitization. J Occup Med 1989; 31:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/18\">",
"      Yarbrough JA, Moffitt JE, Brown DA, Stafford CT. Cimetidine in the treatment of refractory anaphylaxis. Ann Allergy 1989; 63:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/19\">",
"      VanArsdel PP Jr. Allergy to cephalosporins. JAMA 1991; 265:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/20\">",
"      Pepys J, Pepys EO, Baldo BA, Whitwam JG. Anaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis. Anaesthesia 1994; 49:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/21\">",
"      Marcos Bravo C, Luna Ortiz I, Gonz&aacute;lez V&aacute;zquez R. Hypersensitivity to cefuroxime with good tolerance to other betalactams. Allergy 1995; 50:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/22\">",
"      Romano A, Quaratino D, Aimone-Gastin I, et al. Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens. Int J Immunopathol Pharmacol 1997; 10:Suppl 2:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/23\">",
"      Romano A, Quaratino D, Venuti A, et al. Selective type-1 hypersensitivity to cefuroxime. J Allergy Clin Immunol 1998; 101:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/24\">",
"      Grouhi M, Hummel D, Roifman CM. Anaphylactic reaction to oral cefaclor in a child. Pediatrics 1999; 103:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/25\">",
"      Romano A, Quaratino D, Venemalm L, et al. A case of IgE-mediated hypersensitivity to ceftriaxone. J Allergy Clin Immunol 1999; 104:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/26\">",
"      Romano A, Piunti E, Di Fonso M, et al. Selective immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/27\">",
"      Demoly P, Messaad D, Sahla H, et al. Immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/28\">",
"      Bernardini R, Novembre E, Lombardi E, et al. Long persistence of IgE antibody to cefaclor. Allergy 2000; 55:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/29\">",
"      Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000; 106:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/30\">",
"      Romano A, Di Fonso M, Artesani MC, et al. Selective immediate hypersensitivity to ceftazidime. Allergy 2001; 56:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/31\">",
"      Prosser DP, Gompels M. Anaphylactic shock due to cefuroxime in a patient taking penicillin prophylaxis. Paediatr Anaesth 2002; 12:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/32\">",
"      S&aacute;enz de San Pedro B, Mayorga C, Torres MJ, et al. Boosted IgE response after anaphylaxis reaction to cefuroxime with cross-reactivity with cefotaxime. Ann Allergy Asthma Immunol 2002; 89:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/33\">",
"      Ernst MR, van Dijken PJ, Kabel PJ, Draaisma JM. Anaphylaxis after first exposure to ceftriaxone. Acta Paediatr 2002; 91:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/34\">",
"      Baumgartner-Bonnevay C, Choquet-Kastylevsky G, Putet G, et al. [Anaphylactic shock associated with ceftriaxone therapy in a newborn]. Arch Pediatr 2002; 9:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/35\">",
"      Atanaskovi��-Markovi�� M, Gavrovi��-Jankulovi�� M, Cirkovi�� Velickovi�� T, et al. Type-I hypersensitivity to ceftriaxone and cross-reactivity with cefalexin and ampicillin. Allergy 2003; 58:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/36\">",
"      Poston SA, Jennings HR, Poe KL. Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis. Pharmacotherapy 2004; 24:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/37\">",
"      Romano A, Gu&eacute;ant-Rodriguez RM, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005; 35:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/38\">",
"      Butler RH, Gupta R. Postcoital allergic reaction in a woman. J Emerg Med 2005; 28:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/39\">",
"      Worthley DL, Gillis D, Kette F, Smith W. Radiocontrast anaphylaxis with failure of premedication. Intern Med J 2005; 35:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/40\">",
"      Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/41\">",
"      Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships. Ann Pharmacother 2007; 41:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/42\">",
"      Khan R, Anastasakis E, Kadir RA. Anaphylactic reaction to ceftriaxone in labour. An emerging complication. J Obstet Gynaecol 2008; 28:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/43\">",
"      Novembre E, Mori F, Pucci N, et al. Cefaclor anaphylaxis in children. Allergy 2009; 64:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/44\">",
"      Varela Losada S, Gonz&aacute;lez de la Cuesta C, Alvarez-Eire MG, Gonz&aacute;lez Gonz&aacute;lez C. Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime. J Investig Allergol Clin Immunol 2009; 19:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/45\">",
"      Ilhan E, G&uuml;ven&ccedil; TS, Poyraz E, et al. Kounis Syndrome secondary to cefuroxime axetil use in an asthmatic patient. Int J Cardiol 2009; 137:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/46\">",
"      Somech R, Weber EA, Lavi S. Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients. Int Arch Allergy Immunol 2009; 150:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/47\">",
"      Caimmi S, Gal&eacute;ra C, Bousquet-Rouanet L, et al. Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey. Int Arch Allergy Immunol 2010; 153:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/48\">",
"      Barnett AS, Hirshman CA. Anaphylactic reaction to cephapirin during spinal anesthesia. Anesth Analg 1979; 58:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/49\">",
"      Bloomberg RJ. Cefotetan-induced anaphylaxis. Am J Obstet Gynecol 1988; 159:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/50\">",
"      Mizutani H, Ohyanagi S, Shimizu M. Anaphylaxis from cefotiam hexetil hydrochloride (CTM-HE) in an atopic nurse. Clin Exp Dermatol 1996; 21:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/51\">",
"      Nordt SP, Cantrell FL, Rodriguez GJ. Anaphylactic reaction to dermal exposure to cephalexin. Am J Emerg Med 1999; 17:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/52\">",
"      Romano A, Torres MJ, Mayorga C, et al. Allergy to two drugs in a patient. Allergy 2001; 56:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/53\">",
"      Orhan F, Odemis E, Yaris N, et al. A case of IgE-mediated hypersensitivity to cefepime. Allergy 2004; 59:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/54\">",
"      Romano A, Viola M, Gu&eacute;ant-Rodriguez RM, et al. Selective immediate hypersensitivity to cefodizime. Allergy 2005; 60:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/55\">",
"      Kaplan K, Weinstein L. Anaphylaxis to cephaloridine in a nurse who prepared solutions of the drug. JAMA 1967; 200:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/56\">",
"      Scholand JF, Tennenbaum JI, Cerilli GJ. Anaphylaxis to cephalothin in a patient allergic to penicillin. JAMA 1968; 206:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/57\">",
"      Saleh Y, Tischler E. Severe anaphylactic reaction to intravenous cephaloridine in a pregnant patient. Med J Aust 1974; 2:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/58\">",
"      Tadokoro K, Niimi N, Ohtoshi T, et al. Cefotiam-induced IgE-mediated occupational contact anaphylaxis of nurses; case reports, RAST analysis, and a review of the literature. Clin Exp Allergy 1994; 24:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/59\">",
"      Konno R, Nagase S. Anaphylactic reaction to cefazolin in pregnancy. J Obstet Gynaecol (Tokyo 1995) 1995; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/60\">",
"      Warrington RJ, McPhillips S. Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics. J Allergy Clin Immunol 1996; 98:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/61\">",
"      Fujita Y, Chikamitsu M, Kimura M, et al. An anaphylactic reaction possibly associated with an intraoperative coronary artery spasm during general anesthesia. J Clin Anesth 2001; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/62\">",
"      Jao MS, Cheng PJ, Shaw SW, Soong YK. Anaphylaxis to cefazolin during labor secondary to prophylaxis for group B Streptococcus: a case report. J Reprod Med 2006; 51:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/63\">",
"      Tayman C, Mete E, Bayrak O, et al. Unexpected cefazolin anaphylaxis in a 5-month-old girl. Pediatr Emerg Care 2008; 24:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/64\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/65\">",
"      Rothschild PD, Doty DB. Cephalothin reaction after penicillin sensitization. JAMA 1966; 196:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/66\">",
"      Blanca M, Vega JM, Garcia J, et al. New aspects of allergic reactions to betalactams: crossreactions and unique specificities. Clin Exp Allergy 1994; 24:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/67\">",
"      Pham NH, Baldo BA. beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit 1996; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/68\">",
"      Baldo BA. Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions. Clin Exp Allergy 1999; 29:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/69\">",
"      Blanca M, Mayorga C, Torres MJ, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/70\">",
"      Nagakura N, Shimizu T, Masuzawa T, Yanagihara Y. Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams. Int Arch Allergy Appl Immunol 1990; 93:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/71\">",
"      Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/72\">",
"      Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/73\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 2012; 129:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/74\">",
"      Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/75\">",
"      VanArsdel PP Jr. Drug reactions: allergy and near-allergy. Ann Allergy 1986; 57:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/76\">",
"      Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007; 33:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/77\">",
"      Yerushalmi J, Zvulunov A, Halevy S. Serum sickness-like reactions. Cutis 2002; 69:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/78\">",
"      Yawalkar N, Reimers A, Hari Y, et al. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells. Dermatology 1999; 199:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/79\">",
"      Ozkaya E, Mirzoyeva L, Jhaish MS. Ceftriaxone-induced fixed drug eruption: first report. Am J Clin Dermatol 2008; 9:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/80\">",
"      Murray KM, Camp MS. Cephalexin-induced Stevens-Johnson syndrome. Ann Pharmacother 1992; 26:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/81\">",
"      Narayanan VS, Mamatha GP, Ashok L, Rajashekar N. Steven Johnson syndrome due to I.V Ceftriaxone--a case report. Indian J Dent Res 2003; 14:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/82\">",
"      Lam A, Randhawa I, Klaustermeyer W. Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. Allergol Int 2008; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/83\">",
"      Gonzalo-Garijo MA, Rodr&iacute;guez-Nevado I, de Argila D. Patch tests for diagnosis of delayed hypersensitivity to cephalosporins. Allergol Immunopathol (Madr) 2006; 34:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/84\">",
"      Young EJ, Fainstein V, Musher DM. Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population. Rev Infect Dis 1982; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/85\">",
"      Mastella G, Agostini M, Barlocco G, et al. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis. J Antimicrob Chemother 1983; 12 Suppl A:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/86\">",
"      Platt R. Adverse effects of third-generation cephalosporins. J Antimicrob Chemother 1982; 10 Suppl C:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/87\">",
"      Sanders CV, Greenberg RN, Marier RL. Cefamandole and cefoxitin. Ann Intern Med 1985; 103:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/88\">",
"      Akcam FZ, Aygun FO, Akkaya VB. DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J Infect 2006; 53:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/89\">",
"      Suswardana, Hernanto M, Yudani BA, et al. DRESS syndrome from cefadroxil confirmed by positive patch test. Allergy 2007; 62:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/90\">",
"      Fujiwaki T, Yoshikawa T, Urashima R, Ishioka C. Drug rash with eosinophilia and systemic symptoms induced by cefotaxime and ampicillin. Pediatr Int 2008; 50:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/91\">",
"      Garnier A, El Marabet el H, Kwon T, et al. Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following hepatitis A. Pediatr Nephrol 2008; 23:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/92\">",
"      Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/93\">",
"      Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/94\">",
"      Igea JM, Fraj J, Davila I, et al. Allergy to cefazolin: study of in vivo cross reactivity with other betalactams. Ann Allergy 1992; 68:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/95\">",
"      Weber EA. Cefazolin specific side chain hypersensitivity. J Allergy Clin Immunol 1996; 98:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/96\">",
"      Atanaskovi��-Markovi�� M, Cirkovi�� Velickovi�� T, Gavrovi��-Jankulovi�� M, et al. A case of selective IgE-mediated hypersensitivity to ceftibuten. Allergy 2005; 60:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/97\">",
"      Gaig P, San Miguel MM, Enrique E, Garc&iacute;a-Ortega P. Selective type-1 hypersensitivity to cefixime. Allergy 1999; 54:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/98\">",
"      Moreno E, D&aacute;vila I, Laffond E, et al. Selective immediate hypersensitivity to cefepime. J Investig Allergol Clin Immunol 2007; 17:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/99\">",
"      The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998; 101:S465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/100\">",
"      Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/101\">",
"      Testi S, Severino M, Iorno ML, et al. Nonirritating concentration for skin testing with cephalosporins. J Investig Allergol Clin Immunol 2010; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/102\">",
"      Barbaud A, Reichert-Penetrat S, Tr&eacute;chot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/103\">",
"      Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/104\">",
"      Zhao Z, Baldo BA, Rimmer J. beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. Clin Exp Allergy 2002; 32:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/105\">",
"      Harle DG, Baldo BA. Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. Int Arch Allergy Appl Immunol 1990; 92:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/106\">",
"      Sanz ML, Gamboa PM, Ant&eacute;para I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/107\">",
"      Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004; 34:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/108\">",
"      Ebo DG, Sainte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 2006; 61:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/109\">",
"      Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/110\">",
"      De Week AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. J Investig Allergol Clin Immunol 2009; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/111\">",
"      Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999; 83:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/112\">",
"      Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/113\">",
"      Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. J Pediatr 1998; 132:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/114\">",
"      Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/115\">",
"      Romano A, Pietrantonio F, Di Fonso M, Venuti A. Delayed hypersensitivity to cefuroxime. Contact Dermatitis 1992; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/116\">",
"      Martin JA, Alonso MD, L&aacute;zaro M, et al. Delayed allergic reaction to cefonicid. Ann Allergy 1994; 72:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/117\">",
"      San Miguel MM, Gaig P, Bartra J, Garc&iacute;a-Ortega P. Postoperative rash to ceftriaxone. Allergy 2000; 55:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/118\">",
"      Romano A, Di Fonso M, Artesani MC, et al. Delayed hypersensitivity to cefotetan. Allergy 2001; 56:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/119\">",
"      Romano A, Torres MJ, Di Fonso M, et al. Delayed hypersensitivity to cefazolin: report on a case involving lymphocyte transformation studies with different cephalosporins. Ann Allergy Asthma Immunol 2001; 87:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/120\">",
"      Kudva-Patel V, White E, Karnani R, et al. Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia. J Allergy Clin Immunol 2002; 109:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/121\">",
"      Borch JE, Bindslev-Jensen C. Full-course drug challenge test in the diagnosis of delayed allergic reactions to penicillin. Int Arch Allergy Immunol 2011; 155:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/122\">",
"      Blanca-L&oacute;pez N, Zapatero L, Alonso E, et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/123\">",
"      Schnyder B, Pichler WJ. Nonimmediate drug allergy: diagnostic benefit of skin testing and practical approach. J Allergy Clin Immunol 2012; 129:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/55/11130/abstract/124\">",
"      Blanca M, Torres MJ, Garc&iacute;a JJ, et al. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol 1999; 103:918.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13535 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11130=[""].join("\n");
var outline_f10_55_11130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4382970\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4382802\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H518454020\">",
"      CLINICAL MANIFESTATIONS, INCIDENCE, AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H202204\">",
"      Immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H202211\">",
"      - Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207320\">",
"      Possible allergens and cross-reactivity with penicillins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4382830\">",
"      Non-immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4382837\">",
"      - Maculopapular rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4382844\">",
"      - Delayed onset urticaria/angioedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4382851\">",
"      - Other uncommon reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H998584\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4382858\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H204407\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H205961\">",
"      Evaluation of immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H206010\">",
"      - Skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H206017\">",
"      Positive results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H998736\">",
"      Negative results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H206038\">",
"      - In vitro assays for cephalosporin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H206045\">",
"      - Graded challenge (test dosing)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H206081\">",
"      - Risk of resensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H208530\">",
"      Evaluation of non-immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89835615\">",
"      - Challenges for non-immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210967\">",
"      OPTIONS FOR SUBSEQUENT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H211259\">",
"      NATURAL HISTORY OF CEPHALOSPORIN ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4382970\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13535|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/26/6573\" title=\"figure 1\">",
"      Comparison of cephalosporin and penicillin structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/12/40132\" title=\"figure 2\">",
"      Cephalosporin side chains - common moeities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/55/13171\" title=\"figure 3\">",
"      Penicillins and cephalosporins - common side chains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13535|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 1\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27905\" title=\"picture 2\">",
"      Urticarial drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 3\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13535|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5400?source=related_link\">",
"      Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_55_11131="Procedure for sucrose analgesia";
var content_f10_55_11131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure for sucrose analgesia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Painful procedure such as venipuncture or lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Age &lt; 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant is restricted from oral intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Use a 25 percent sucrose solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Administer 2 mL, perferably by allowing the infant to suck on a pacifier, or with a syringe, 1 mL in each cheek",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Administer no more than 2 minutes before beginning painful procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. May repeat the dose but not to exceed two doses in one hour",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11131=[""].join("\n");
var outline_f10_55_11131=null;
var title_f10_55_11132="Diseases IgM deficiency";
var content_f10_55_11132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases associated with symptomatic IgM deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchitis, pneumonia, sinusitis, otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased atopy: allergic rhinitis, asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial lung disease?*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis (meningococcal, others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcal naspopharyngitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized vaccinia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermodysplasia verruciformis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupational small pox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent staphylococcal pyoderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated molluscum contagiosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hashimoto's thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic idiopathic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplastic Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear cell sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolymphocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohns disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blooms syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to train (athlete)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary interstitial disease?*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Possible association.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11132=[""].join("\n");
var outline_f10_55_11132=null;
var title_f10_55_11133="Pathophysiology Eisenmenger";
var content_f10_55_11133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of the Eisenmenger syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Vongpatanasin, W, Brickner, E, Hillis, LD, et al, Ann Intern Med 1998; 128:749.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11133=[""].join("\n");
var outline_f10_55_11133=null;
var title_f10_55_11134="Probability of HF women";
var content_f10_55_11134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of heart failure within four years for women aged 45 to 94 years with coronary disease, hypertension, or valvular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Variables",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"10\" rowspan=\"1\">",
"       Points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       0",
"      </td>",
"      <td class=\"subtitle2\">",
"       +1",
"      </td>",
"      <td class=\"subtitle2\">",
"       +2",
"      </td>",
"      <td class=\"subtitle2\">",
"       +3",
"      </td>",
"      <td class=\"subtitle2\">",
"       +4",
"      </td>",
"      <td class=\"subtitle2\">",
"       +5",
"      </td>",
"      <td class=\"subtitle2\">",
"       +6",
"      </td>",
"      <td class=\"subtitle2\">",
"       +7",
"      </td>",
"      <td class=\"subtitle2\">",
"       +8",
"      </td>",
"      <td class=\"subtitle2\">",
"       +9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age, y",
"      </td>",
"      <td>",
"       45-49",
"      </td>",
"      <td>",
"       50-59",
"      </td>",
"      <td>",
"       60-69",
"      </td>",
"      <td>",
"       70-79",
"      </td>",
"      <td>",
"       80-89",
"      </td>",
"      <td>",
"       90-94",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Forced vital capacity, cL",
"      </td>",
"      <td>",
"       &gt;299",
"      </td>",
"      <td>",
"       250-299",
"      </td>",
"      <td>",
"       200-249",
"      </td>",
"      <td>",
"       150-199",
"      </td>",
"      <td>",
"       &lt;150",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systolic blood pressure, mmHg",
"      </td>",
"      <td>",
"       &lt;130",
"      </td>",
"      <td>",
"       130-189",
"      </td>",
"      <td>",
"       &gt;189",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart rate, bpm",
"      </td>",
"      <td>",
"       &lt;55",
"      </td>",
"      <td>",
"       55-79",
"      </td>",
"      <td>",
"       80-99",
"      </td>",
"      <td>",
"       &gt;99",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LVH on ECG",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\">",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coronary heart disease",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiomegaly",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Valve disease",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes, no valve disease",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes, valve disease",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Points",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"       4-Year probability of heart failure, percent",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Points",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       4-Year probability of heart failure, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       5",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       &lt;1",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       26",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       18",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       10",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       1",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       27",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       12",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       1",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       28",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       24",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       14",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       2",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       29",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       28",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       16",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       3",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       30",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       18",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       4",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       31",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       37",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       20",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       9",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       32",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       42",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       22",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       13",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       33",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       24",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       13",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       34",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       51",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       25",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       15",
"      </td>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       35",
"      </td>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       56",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LVH: left ventricular hypertrophy; ECG: electrocardiogram; cL: centiliter; y: years; bpm: beats per minute.",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: Kannel WB, D'Agostino RB, Silbershatz H, et al. Arch Intern Med 1999; 159:1192.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11134=[""].join("\n");
var outline_f10_55_11134=null;
var title_f10_55_11135="Discoid malacia CT";
var content_f10_55_11135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Discoid trachea due to tracheomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan shows a narrow sagittal diameter and wide coronal diameter of the trachea. These findings are the opposite of those associated with a saber sheath trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_55_11135=[""].join("\n");
var outline_f10_55_11135=null;
